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ABSTRACT 
Mao, Shihong. Ph.D., Department of Computer Science a d Engineering, Wright State 
University, 2007. Comparative Microarray Data Mining. 
 
 
 
As a revolutionary technology, microarrays have great potential to provide genome-wide 
patterns of gene expression, to make accurate medical diagnosis, and to explore genetic 
causes underlying diseases. It is commonly believed that suitable analysis of microarray 
datasets can lead to achieve the above goals. While much has been done in microarray 
data mining, few previous studies, if any, focused on multiple datasets at the comparative 
level. This dissertation aims to fill this gap by developing tools and methods for set-based 
comparative microarray data mining. Specifically, we mine highly differentiative gene 
groups (HDGGs) from given datasets/classes, evaluate the concordance of datasets 
generated from different platforms/laboratories, investigate the impact of variability in 
microarray dataset on data mining results, provide tools and algorithms for the above 
tasks, and identify reliable invariant HDGG patterns for better understanding diseases. 
It is a big challenge to discover high-quality discriminating (emerging) patterns from high 
dimensional microarray datasets. We develop a novel feature-group selection method to 
help discover HDGGs, especially signature HDGGs that completely characterize some 
disease classes. In addition to giving insights on the diseases, better classification results 
are also obtained using HDGG-based classifiers compared with other existing classifiers. 
As microarray datasets are often generated from different platforms/laboratories, it is 
necessary to evaluate their concordance/consistence before they can be studied together. 
We provide measures and techniques to quantitatively test such concordance at the 
 v 
comparative level.  
In addition to applying measures to evaluate the degree of variability in microarray 
datasets, we also develop a novel algorithm called C-loocv to effectively minimize the 
variability. As an indicator of the utility of C-loocv, classifiers trained from C-loocv-
refined datasets become more robust and predict test samples at significantly higher 
accuracy over classifiers trained from original datasets. 
Based on the variability minimization algorithm, we provide a novel strategy to mine 
invariant patterns from multiple datasets concerning a common disease. As a 
demonstration, invariant patterns are identified from two datasets concerning lung cancer; 
these patterns may shed light on the mechanism underlying the pathogenesis of lung 
cancer. Our methods are generic and can be applied to microarrays concerning any 
human diseases. 
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Chapter 1: INTRODUCTION  
 
1.1. MOTIVATION – THE PROSPECT OF MICROARRAY GENE 
EXPRESSION DATA 
Microarray technology allows the measuring of the expr ssion level of thousands of 
genes simultaneously by using gene chips. This technology provides the possibility of 
creating datasets that capture the information concerning all the relevant genes and 
proteins for many systems of biological and clinical interest. Such datasets may help 
scientists explore gene expression patterns and discover gene interaction networks, and 
perhaps even pathways underlying various diseases and biological processes. Such 
discoveries can in turn lead to better understanding of the physiological functions in 
healthy and diseased cells, and to better ways to diagnose and treat diseases. Large-scale 
transcription analyses using microarrays can reveal the molecular mechanisms of 
physiology and pathogenesis, and therefore can help scientists to develop new diagnostic 
and therapeutic strategies. 
Recently, microarray (DNA chip) technology is becoming a very important and powerful 
tool in almost every field of biomedical research. This technology has been used in 
reproductive medical research including study of oocyte fertilization, early embryo 
development, implantation and some infertility-relat d diseases such as endometriosis 
and myoma (Chen et al, 2006). Microarray also brings ew insights into evolutionary 
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biology by providing genome-wide patterns of gene expr ssion within and between 
species (Ranz et al, 2006).  
For cancer study, a number of cancer-related datasets such as colon cancer (Alon 1999), 
acute lymphoblastic leukemia (Golub 1999), breast cncer (van’t Veer et al 2002) and so 
on have been successfully generated using microarray technology in the past decade. 
These datasets have also been widely studied by researchers in various fields, and the 
analysis results have provided valuable information for biomedical, pharmaceutical, and 
clinical research. In the present dissertation several public cancer-related microarray 
datasets were employed for data mining. The long-term goal of this project is to provide 
useful tools and information aiming at enhancing our understanding of diseases by 
developing comparative data mining methods. 
Specifically, we develop several novel comparative data mining approaches on 
microarray gene expression data, aiming at extracting reliable patterns from microarray 
datasets. We propose that comparative data mining of microarray data has the potential to 
discover key groups of genes in cancer, which will he p us to better understand its patho-
physiology. Moreover, this approach will help uncovering new therapeutic targets for 
diseases, predicting how patients respond to specific treatments, and revealing possible 
regulatory relationships among genes in normal and disease situations. 
 
1.2. OVERVIEW OF RESULTS 
In this dissertation, we provide measures, tools and methodologies for the above 
mentioned data mining approaches. Below is a summary of the research projects we have 
been working on: 
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1. Identification of highly differentiative gene groups (HDGGs) from microarray data. 
The aim is to introduce methods that could do a better job given the high dimensionality 
challenge. We combine a new approach (gene club formation) with previous data mining 
algorithms for feature selection and discovering emerging (discriminating) patterns. The 
HDGGs mined from each dataset are considered as discrim native characteristic patterns 
and are important features for each specific dataset. 
2. Multi-source microarray platform concordance detection. The aim is to provide 
measures and techniques to compare microarray gene expr ssion data generated from 
different platforms and laboratories. Microarray datasets are generated from different 
platforms / laboratories. It is necessary to evaluate the concordance and consistence of the 
multi-source microarray datasets before they can be applied to clinical, pharmaceutical 
research and other purposes. Since no comparative methods have been applied to test the 
concordance of multi-source microarray datasets, we generated several comparative 
methods to test such data and measure their concordance with each other.  
3. Minimization of microarray dataset variability. The aim is to evaluate the effect of 
variability on data mining results and to provide novel methods to minimize it. The 
inevitable variability in microarray datasets leads to less reliability and accuracy of mined 
patterns and models. We develop a novel method to minimize variability by eliminating 
highly noisy samples from datasets. 
4. Identification of invariant patterns. The aim is to mine reliable patterns thought to play 
key roles in the pathogenesis of diseases. We provide a novel method to mine invariant 
patterns from multiple datasets related to a disease in particular. The invariant patterns 
(shared gene interactions) are considered as more reliable patterns and expected to 
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provide useful information for potential gene pathways for the diseases under 
consideration. 
1.3. ORGANIZATION OF THE DISSERTATION  
This dissertation deals with comparative microarray d ta mining, and is divided in eight 
chapters. Chapter 1 is an introduction chapter. Chapter 2 gives an overview of 
preliminary information on gene expression data, and  discussion of some important 
concepts which will be applied in other chapters, such as high dimension, high variability 
microarray data, emerging patterns, entropy-based discretization method and information 
gain. Chapter 3 provides a review of the literature on topics related to the present research. 
This chapter discusses what have been done by previous researches, the gaps that exist 
between current research and our research goals, and what we want to do in order to fill 
these gaps. 
Discovery of invariant 
patterns
(Chapter 7)
Dataset concordance 
detection
(Chapter 5) 
Discovery of HDGGs
(Chapter 4)
Variability evaluation 
and minimization
(Chapter 6)
Multi-source microarray datasets
Comparable?
Reliable?
if yes
if yes
 
Figure 1.1: Outline of topics studied in this dissertation. 
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Chapters 4 to 7 comprise the results from the scientific research accomplished during the 
past 5 years. Chapter 4 introduces the discovery and application of HDGGs. Chapter 5 
deals with the detection of concordance of microarray datasets generated from different 
platforms / laboratories. Chapter 6 presents our investigation on and the minimization of 
biological variation in microarray datasets. Chapter 7 discusses the discovery of invariant 
patterns from multi-microarray datasets. Chapter 8 is a summary of our work and future 
directions.  
The relationship between the topics considered in this dissertation is illustrated in Figure 
1.1. 
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Chapter 2: PRELIMINARIES  
 
This chapter deals with background information regading the techniques and 
terminology that will be used throughout this dissertation. 
2.1. MICROARRAY GENE EXPRESSION DATA  
With the development of microarray technology many kinds of microarray data have 
been generated such as: DNA microarrays, protein microarrays, tissue microarrays, cell 
microarrays, chemical compound microarrays and antibody microarrays. The most 
commonly used ones are DNA microarrays. In this disertation, “microarrays” refers to 
“DNA microarrays”. 
A DNA microarray (also commonly known as a gene or genome chip, DNA chip, or gene 
array) is a collection of microscopic DNA spots, each representing a gene probe, arrayed 
on a solid surface by covalent attachment to chemically suitable matrices. DNA arrays 
differ from other types of microarrays only in that they either measure DNA or use DNA 
as part of its detection system. Qualitative or quantit tive measurements with DNA 
microarrays utilize the selective nature of DNA-DNA or DNA-RNA hybridization under 
high-stringency conditions and use fluorophore-based d tection. DNA microarrays are 
commonly used for expression profiling, i.e., monitring gene expression levels of 
thousands of genes simultaneously to determine whether hose genes are active, 
hyperactive or silent in given tissues. 
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Figure 2.1 shows the step by step procedure to convert each gene’s expression level into a 
real numeric value data when using microarrays. 1) A microarray chip is labeled with 
gene probes (left column). 2) Total mRNA is extracted from a given sample and labeled 
with the corresponding fluorophore, e.g. cy3 or cy5(middle column). 3) The microarray 
is hybridized with labeled mRNA (middle). 4) The microarray is scanned, filtered and 
raw data is generated (right column). 5) After data preprocessing and normalization, the 
data generated can be used for further analysis and mi ing. Table 2.1 is an example of 
microarray gene expression data with three genes and six tissues (three from normal 
control, and three from diseased patients).  
 
 
Figure 2.1: Microarray technology pipeline 
 
ORF: open reading frame, PCR: polymerase chain reaction 
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Table 2.1:  A sample microarray gene expression dataset 
 d1 d2 d3 N1 n2 n3 
g1 32.0 52.3 89.3 51.1 29.7 4.5 
g2 5.9 1.7 2.6 10.0 3.2 9.1 
g3 94.4 132.7 180 73.4 55.8 120.6 
 
d1, d2, d3: diseased tissues; n1, 2, n3: normal tissues; g1, g2, g3: genes. 
 
Currently microarray data are generated using various different platforms such as 
commercial platforms (Affymetrix, Agilent, Applied Biosystems, etc) or custom-made 
ones. The platforms mainly differ on what and how the gene probes are labeled on the 
microarray chips. For example, the probes on the Agilent platform are cDNA, which is 
reverse-transcribed from known mRNA. The probes can perfectly hybridize with their 
corresponding mRNA, although the quality of the probes may greatly affect the 
hybridizing results. Affymetrix is probably the most popular commercial platform so far. 
The probes are designed based on gene sequence analysis. Each probe on the chip is 
designed as one pair of oligonucleotide about 35 mer in length. One oligonucleotide is 
the Perfect-Match (PM), and the other one is a one-base pair Mis-Match (MM), with the 
corresponding gene. This probe design can effectively reduce noise in microarray data.  
 
2.2. CHARACTERISTICS OF MICROARRAY DATA  
Compared with commercial datasets, microarray gene expression datasets have quite 
different characteristics. First, their dimensionality, i.e. the number of features explored 
in gene chip, is high. The raw microarray images are transformed into gene expression 
matrices where the rows usually denote genes or features and the columns denote various 
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samples, conditions, tissues or instances. The number of features (dimensions) can be 
very high. Usually, there are usually thousands of gene probes in one gene chip. If a gene 
chip is designed to detect all genes in a human tissue ample, the number of probes may 
exceed 100,000.  
Second, the number of samples may be small, compared with typical commercial 
applications. For many biomedical and pathology studies, the number is usually less than 
200.  
Third, microarray datasets may be very noisy containing unreliable or contaminated 
values. In sum, there is high variability in microaray datasets. The variability includes 
that inherent to measurement procedures (measurement variability) and biological 
variation. Measurement variability results from differences in experimental conditions, 
procedures and differences in microarray technologies. Biological variation is due to 
intrinsic characteristics of the samples. 
Table 2.2:  An ideal microarray gene expression dataset 
 Class A Class B 
 s1 … sx s1 … sy 
g1 a1 … a1 b1 … b1 
g2 a2 … a2 b2 … b2 
… … … … … … … 
gn an … an bn … bn 
 
Ideally, if there is no variability, each gene’s expression value across the samples within 
one class should be identical. Table 2.2 shows a sample microarray gene expression 
dataset without variability. There are two classes A and B in this dataset. There are x 
samples (s1 to sx) in A and y samples (s1 to sy) in B. Total n gene probes (g1 to gn) are 
used to construct the microarray chip. ai and bi are gene gi’s standard values in class A 
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and B respectively. Under the ideal situation, gi’s real value in any samples in one class 
should be equal to its standard value. In this case, data mining results from this dataset 
will be 100% accurate and reliable. Unfortunately this kind of microarray dataset never 
exists in reality. 
Table 2.3 shows microarray dataset with measurement variability. Each gene’s detected 
value aij  and bik (1 ≤i ≤ n, 1 ≤j ≤x, 1 ≤k ≤y) is shifted from its standard value by a random 
value αij or βik. If αij  or β ik is large, then the data have high variability.  
 
Table 2.3:  Microarray gene expression dataset with only measurement variability 
 
 Class A Class B 
 s1 … sx s1 … sy 
g1 a1± α11 … a1± α1x b1± β11 … b1± β1y 
g2 a2± α21 … a2± α2x b2± β21 … b2± β2y 
… … … … … … … 
gn an± αn1 … an± αnx bn± βn1 … bn± βny 
 
 
As mentioned before, besides measurement variability, there is also intrinsic biological 
variation in microarray datasets. Microarray datasets are typically generated using tissue 
samples from different patients. These patients have different characteristics such as 
height, weight, age, race, and sex. These differencs inevitably lead to biological 
variations in microarray datasets. Because of biolog cal variation, gene gi’s standard 
values (ai or bi) can not be measured. In reality, in different samples, the “real” values of 
gi are different. For example, in class A, gi’s real value at sample j is aij nd gi’s detected 
value at sample j will be aij ± αij. Theoretically, gi’s real value should be close to its 
standard value within one class; however, in real microarray dataset, some samples have 
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big biological variation because the genes’ real values in these samples are far away from 
their standard value. 
  
Table 2.4:  Actual microarray gene expression dataset 
 
 Class A Class B 
 s1 … sx s1 … sy 
g1 a11± α11 … a1x± α1x b11± β11 … b1y± β1y 
g2 a21± α21 … a2x± α2x b21± β21 … b2y± β2y 
… … … … … … … 
gn an1± αn1 … anx± αnx bn1± βn1 … bny± βny 
 
Table 2.4 shows a realistic microarray dataset. Both measurement variability and 
biological variation are included. The high variability may affect the reliability of 
microarray datasets. During microarray data analysis and data mining, the high variability 
should be considered. 
 
2.3. EMERGING PATTERNS AND BORDER DIFFERENTIAL 
ALGORITHM  
Emerging patterns (EPs) (Dong et al., 1999; Dong et al., 2005) are defined as patterns 
whose supports increase significantly from one class to another. EPs with growth rate 
(defined as the ratio of frequency between the classes) of infinity are called jumping EP 
(JEP), i.e. these patterns appear in one class but never exist in other classes. EPs have 
been proved to be very useful as a means of discovering distinctions inherently present 
between different classes of data. For example, by using emerging patterns, Li and 
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colleagues (Li et al., 2002, Li et al., 2003a, Li et al., 2003b) identified good diagnostic 
genes or gene groups from gene expression data of the Acute Lymphoblastic Leukemia 
vs Acute Myeloid Leukemia (ALL/AML) dataset (Golub et al., 1999) and other datasets 
such as colon cancer (Alon et al., 1999) and ALL (Yeoh et al., 2002). 
To efficiently discover the jumping emerging patterns (JEPs) with respect to a positive 
dataset and a negative dataset, border manipulation lg rithm was proposed (Dong et al., 
1999). The border differential algorithm is the core subroutine for JEP mining and it aims 
to derive the difference between a pair of border of a special form. The border based 
algorithm achieves high efficiency by manipulating only the itemsets in the borders and 
avoiding the tedious process of enumerating all the individual JEPs. 
 
2.4. ENTROPY-BASED DISCRETIZATION METHOD AND 
INFORMATION GAIN 
Microarray gene expression data are always continuous and contain a large number of 
genes. Such data should be pre-processed, through operati ns including binning, 
duplicate gene removal, and gene ranking. Binning transforms continuous features into 
discrete features. The entropy based method (Dougherty et al., 1995) is often applied to 
convert the values for each gene into two intervals (bins) and to rank the genes. (More 
bins can be allowed, but in this dissertation we only consider two bins.) One bin will be 
called “high” and the other “low”. Let S be the set of all tuples and T(S, Cj) be the 
proportion of tuples in S that have class Cj. The entropy for S is: 
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Let g be a gene. Each value v can divide g’s values into two intervals, namely g ≤ v and g 
> v; let S1 (resp., S2) be the set of tuples in S where g’s values are ≤ v (resp., > v). We 
define Entropy(Si) similarly as above. The class information for gene g at partition point 
v is 
)(*
||
||
)(*
||
||
),( 2
2
1
1 SEntropy
S
S
SEntropy
S
S
vgI +=
 
where |S| denotes the cardinality of S. The information gain for g at partition point v is: 
),()(),( vgISEntropyvgInfoGain −=  
The value v for which InfoGain(g,v) is maximal amongst all the candidate split points is 
selected as the split point for g. Let InfoGain(g) denote that maximal InfoGain(g, v).  
Information gain for a gene captures how strong the gene is related to the class; the larger 
the information gain, the stronger the relationship. We will usually rank the genes in 
decreasing information gain order. 
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Chapter 3: LITERATURE REVIEW 
The main goal of the present dissertation is to find new ways to analyze microarray gene 
expression datasets so that we can mine more information out of them and hopefully 
provide valuable clues for biological and medical research.  One of the strength of this 
research is to compare multiple datasets. In addition, microarray analysis and data mining 
have potential value as a diagnostic and predictive tool in various researches. 
This chapter comprises a survey of the work related to our study, identify the gaps 
between previous studies and our research goals, and briefly introduce what we are going 
to do to fill those gaps. The main topics include comparative studies and data mining, 
feature selection, microarray data concordance detection, biological variation, instance 
selection and classification. 
 
3.1. COMPARATIVE STUDIES AND DATA MINING 
Comparative studies, aimed at comparing the similarity/difference between groups using 
comparative methods, have been applied to many fields, such as genomics, gene function 
comparison, text files and microarray datasets. In the field of genomics, comparative 
study, commonly named comparative genomics, is used to study the similarities and 
differences in the structure and function of hereditary information across species. This 
approach is used to compare genomes in genomics comparative data analysis. Recently, 
the availability of sequences from numerous biological species has allowed multiple 
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species-comparisons for identifying the relationship  between species (Hood et al 1995, 
Dubchak et al 2000, Pennacchio et al 2001, Gottgens et al 2002). The utility of 
comparative sequence analysis is based on the hypothesis that important biological 
sequences are conserved between species due to functi nal onstraints.  
A number of recent comparative genomics studies, such as the evolutionary distance 
comparison between human-mice, human-birds, human-fish and human-primate, have 
yielded the identification of functional sequences solely through the use of genomic 
comparison. Enormous advances, such as the inference of function of new sequences 
through similarity to known sequences, have been made (Boffelli et al, 2003, Kappen et 
al, 2003, Harris et al, 2003, Nobrega et al, 2003, Postlethwait et al, 2000, OBrien et al, 
1999).  
Similarly, comparative studies have been applied on ge e function comparison. Lin and 
colleagues (Lin et al., 2002) proposed a new concept alled “functional genomic units”, 
which is a group of genes carrying out some common biological functions. They 
described an interesting attempt to use the Rosetta dat set (cDNA platform) to 
corroborate a Rac1 transfection obtained from Affymetrix platform.  
When data mining approaches are applied to compare different datasets / classes and to 
find similarity patterns and unique patterns between these datasets, then the comparative 
study is called comparative data mining. Comparative data mining has been applied on 
text files, which is named as comparative text mining. Zhai and colleagues (Zhai et al, 
2004) proposed a generative probabilistic mixture model for comparative text mining. By 
using this model, they discovered certain latent comm n themes across all collections and 
summarized the similarities and differences of these collections along each common 
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theme. This approach could be adopted to study microarrays to find common /unique 
patterns from mutli-datasets.  
If comparative data mining is applied to study microar ay datasets, we call it 
“comparative microarray gene expression data mining”. This term is first mentioned in 
this dissertation and will be its main focus. Comparative data mining is defined as the 
mining of similarities and differences/contrasts among multiple data classes or multiple 
datasets (each with or without classes).  
According to this definition, few papers, if any, can be considered to fall within the 
categories of comparative microarray data mining. One paper mentioned comparative 
data mining on microarrays (Page et al 2002). The authors used comparative data mining 
experiments to compare various classification methods and to identify the advantages of 
the leading supervised learning algorithms for microar ay data. It should be pointed out 
that comparing multiple methods on one dataset will not be considered as comparative 
data mining, in the sense defined above. 
Many data mining methods focus on feature selection and classification methods by using 
microarray data (Li et al 2004). Strictly speaking, building classifiers can not be 
considered as comparative data mining, although it is considering two or more classes 
and hence it can be loosely considered as comparative mining. Other studies use 
comparative methods to analyze microarray data (Xing et al 2001). In their studies, they 
use statistical methods other than data mining for mic oarray data study. 
So far, many methods have been proposed for the analysis of microarray data. In general, 
some of these methods were borrowed from data mining i  other areas and ignored the 
intrinsic biological features of microarray data. Most importantly, few of these methods 
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considered the high variability in microarray datasets or the concordance between 
multiple datasets, which may greatly affect the reliabi ity of data mining results. The 
present dissertation addresses these fundamental issues by using comparative microarray 
data mining. 
 
3.2. FEATURE SELECTION 
Feature selection aims at selecting a subset of relevant features for building robust 
learning models. It has been extensively studied in machine learning. Feature selection 
helps to improve the performance of learning models by enhancing generalization 
capability; speeding up learning processes; and improving model interpretability. In 
microarray studies, feature selection is called discriminative gene selection. It selects the 
influential genes based on their ability to distinguish between various classes of samples, 
such as between different types of diseases or between diseased and healthy states. Thus, 
feature selection can help to better understand microarray data, and tell which genes are 
important and how they are related with each other.  
One characteristic of microarray data is their considerable number of features (genes). 
Among these features, not all of them carry relevant information for a particular 
application. It is necessary to use feature selection o select the most important 
components. From a biological perspective, the most c mmon situation is a group of 
genes work together rather than a single gene in the genesis of a disease (Cunliffe et al., 
2003, Califano et al., 2000, Segal et al., 2003). Thus, feature selection is a useful tool to 
detect groups of genes from microarray datasets, by considering genes’ interaction with 
other genes.  
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In gene expression analysis studies, many gene (feature) selection methods have been 
developed. These methods include information gain, towing rule, sum minority, max 
minority, Gini index, sum of variances, one-dimensio al SVM, t–statistics, the ratio of 
between-groups to within-groups sum of squares (BSS/ W S), principal component 
analysis among others (Su et al., 2003). Information gain and Gini index are widely used 
in machine learning. Towing rule, max minority, sum minority and sum of variances are 
broadly applied in statistical learning theory. In these methods, the full range of 
expression of a given gene is split into two regions: high or low. Then the strength of this 
given gene with respect to the class is evaluated. One-dimensional SVM (Brown et al., 
2000; Ramaswamy et al., 2001) measures the effectiveness of a future by calculating the 
accuracy of single-feature SVM classifiers. t -stati ics was first used by Golub and 
colleagues to measure the class predictability of genes for two-class problems (Golub et 
al., 1999). 
In many of the methods mentioned above, genes are typically grouped by similarity of 
their expression profiles. We suggest a different approach in which genes are grouped 
together when correlation of their expression profiles n one state is destroyed in another 
state. The correlation considered here is general (.g., one gene is high whenever another 
is low). A highly differentiative gene group (HDGG) is a gene group in which genes are 
correlated with each other. A HDGG captures the following information: in the normal 
state, some genes are correlated (perhaps because they participate in some common 
pathway under normal situation) and are fully “in sy c”, but in a disease state these genes 
are no longer “in sync” (perhaps because the pathway is disrupted).  
Since microarray data have thousands of dimensions, discovery of gene groups, such as 
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HDGGs, is a big challenge. Exhaustive search is impossible, since the required search 
time grows exponentially with the number of dimensio . Li and colleagues (Li et al., 
2001) use the top-k approach to get around the dimensionality hurdle by selecting the 
globally top-k genes in decreasing information gain (Dougherty et al.,1995) order and 
then applying the border differential algorithm (Dong et al., 1999, Dong et al., 2005) on 
these genes. The border differential algorithm can effectively handle up to 75 genes for 
current generation PCs, but can not finish in reason ble amount of time when higher 
dimensions are present. As will be shown in Chapter 4, the best HDGGs may contain 
genes which are very low in information gain rank, and may be missed by the top-k 
method. We aim to introduce methods that are more effective given the dimensionality 
challenge.  
In order to overcome the high dimension and find HDGGs, we establish gene clubs for 
each given gene by using several methods that will be discussed later in this dissertation. 
Although the determination of gene clubs shares similarities with traditional feature 
selection, it has some new characteristics and is based on the interaction among genes. 
 
3.3. MICROARRAY DATA CONCORDANCE DETECTION  
Microarray technology allows simultaneous measurements of mRNA expression of 
thousands of genes. This technology provides the possibility of creating datasets that 
capture the information concerning all the relevant genes and proteins for many systems 
of biological or clinical interest. Such datasets are useful because they may help scientists 
to discover gene interaction networks, and perhaps even pathways underlying various 
diseases and biological processes. Such discoveries can in turn lead to better 
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understanding of the biological processes and diseases, and to better ways to diagnose 
and treat diseases.  
Recent advances in microarray technology have generated large amounts of gene 
expression data, collected using a variety of commercial platforms from different 
laboratories. The concordance/consistency of the datasets from different sources should 
be evaluated before this technology can be successfully and reliably applied in 
biological/clinical practice and regulatory decision-making (Shi et al., 2004, Hackett et 
al., 2003, Petricoin et al., 2002b). This need was also recognized in recent publications 
addressing some possible factors affecting the consiste cy of DNA microarrays (Guo et 
al, 2006, Shi et al, 2006).  
As mentioned in Section 2.2, two major factors, experimental noise and biological 
variation may cause inconsistent results in repeated experiments during data generation in 
microarray experiments. Experimental noise can be caused by differences in probe 
labeling efficiency, RNA concentration or hybridization efficiency, image analysis and so 
on. All types of such noise might make the experiments unrepeatable. As a result, the 
expression levels reported by a microarray experiment might not exactly reflect the true 
gene expression levels. Biological variation will be discussed in next section. 
There has been wide interest in the intra- and inter-platform comparisons of gene 
expression values (Kuo et al., 2002, Tan et al., 2003b, Hardiman, 2004, Shi et al., 2005, 
Guo et al, 2006, Shi et al 2006). These studies reached different conclusions: On one 
hand, some cross platform comparisons reported a failure to demonstrate an acceptable 
level of correlation between different microarray technologies (Tan et al., 2003b, 
Jarvinen et al., 2004, Woo et al., 2004, Yauk et al., 2004, Mah et al., 2004, Cicatiello et 
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al., 2003, Marshall 2004); the authors conjectured that the difficulties in correlating data 
may be attributed to fundamental differences between cDNA and oligonucleotide based 
microarray technologies. Other studies concluded that low inter-platform consistency is 
due to other reasons instead of inherent technical d fferences among different platforms 
(Shi et al. 2005). Recent studies related to microarray quality control (MAQC) project 
showed that the microarray data from different platforms are fairly concordant (Guo et al 
2006, Shi et al 2006). 
It is not easy to tell how concordant two datasets are. Different criteria (testing methods) 
may give different answers. Most studies have focused on the expression values of 
individual genes. They are not applicable for comparative studies, where one compares 
one class of data against another class. Comparative microarray analysis can better 
distinguish phenotypes from related phenotypes; ident fy valid differentially expressed 
genes by combining many studies; test new hypothesis; and discover fundamental 
patterns of gene regulation. In order to get reliable results when using comparative 
methods, it is desirable to test the datasets’ concordance using the same comparative 
methods. 
The present work introduces novel comparative methods f r evaluating concordance of 
microarray data collected from different laboratories and/or different platforms. These 
methods evaluate concordance by measuring quality preservation of discriminating genes 
and classifiers. Considering that microarray datasets are generated from different 
platforms, if the microarray datasets are concordant with each other with respect to 
discriminating genes, then the knowledge on discriminating genes gained from one 
platform/lab can be transferred to another platform/lab (Mao & Dong et al, in 
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preparation). 
 
3.4. BIOLOGICAL VARIATION 
As mentioned in Section 2.2, two major factors: experimental noise and biological 
variation, may cause inconsistent results in repeated experiments. Experimental noise can 
arise at any step of microarray experiments. It might render the experiment non-
reproducible. As a result, the expression levels report d by a microarray experiment 
might not exactly reflect the true mRNA levels. Biological variation refers to the natural 
variation we would expect to encounter even under ial experimental conditions. In 
other words, even if we could sidestep experimental issues, magically looking inside the 
cells and counting the mRNA molecules of interest, we would still expect some variation 
in counts between cells in the same category (Piatetsky_Shapiro et al, 2003). 
Different from experimental noise, biological variation inevitably exists in microarray 
dataset because of the variety among tissue samples (e.g. patients). Biological variation 
may also affect the accuracy of data analysis and may lead to unreliable results. So far, 
there are few, if any, studies to investigate how biological variability affects to data 
mining results and how to reduce it in microarray dtaset. Liu and colleagues (Liu et al, 
2003) selected samples according to the patient’s surviving time. This selection can be 
applied to some specific datasets but not to all microarray datasets.  
In order to mine reliable patterns, the biological v riability in microarray datasets needs 
to be considered. In this study, first we investigate the influence of variability on our 
comparative study and then we provide methods to minimize it.  
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3.5. INSTANCE SELECTION 
Instance selection aims to search for a representative data subset that replaces the original 
dataset, still solving a data mining task as if the whole dataset were used. Finding a small 
set of representative instances for large datasets can bring various benefits to data mining 
practitioners (Zhu et al 2006): 1) build a learner superior to the one constructed from the 
whole massive data; 2) avoid working on the whole original dataset all the time; and 3) 
remove irrelevant instances as well as noise and/or redundant data. For most data mining 
tasks, such as classification and clustering tasks, the selected dataset should preferably 
exclude noisy instances. Many instance selection algorithms have been developed so far.  
Sampling: Sampling, a basic instance selection, is a well establi hed statistical technique 
that selects a part from a whole to make inferences about the whole, which is applied to 
overcome problems caused by high attribute dimensionality as well as large data volumes 
in data mining. It can profitably used to estimate characteristics of a population of interest 
with less cost, hihger speed, greater scope and probably greater accuracy compared to a 
complete enumeration. It has been applied in different domains of real world application. 
Many sampling-based algorithms have been proposed. According to their relations and 
characteristics, these methods can be classified into d fferent categories.  
Genetic algorithm (GA) based instance selection: Genetic algorithms (Holland, 1975) 
have been successfully applied to various problems (Goldberg, 1989). Genetic algorithm 
can be viewed as a general-purpose optimization technique in discrete search spaces. 
They are suitable for complex problems with multi-model objective functions. Their 
application to instance selection was proposed by Kuncheva (Kuncheva, 1995) for 
designing nearest neighbor classifiers. In her study, the classification performance of 
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selected instances was maximized. A penalty term with respect to the number of selected 
instances was added to the fitness function of her subsequent genetic algorithms 
(Kuncheva, 1999). Later on, a generic algorithm-based approach was used for 
simultaneously selecting instances and features (Liu, et al, 2001). Through computer 
simulations, the authors demonstrated that a small number of instances can be 
successfully selected together with only significant features by their genetic algorithm. 
They also demonstrated that the generalization ability of nearest neighbor classifiers was 
improved by the instance and feature selection in some datasets. 
There are many other instance selection methods which are similar to those mentioned 
above. These methods can reduce the number of instances in datasets, but they didn’t do 
anything for the noise instance removal. The following methods consider how to detect 
and eliminate the noisy instances. 
Iterative case filtering algorithm: Iterative case filtering algorithm (ICF) was 
introduced by Liu and colleagues (Liu et al, 2001). They improved the repeated Wilson 
algorithm investigated by Tomek (Tmoek 1976) by applying a rule which identifies cases 
that should be deleted. In the ICF algorithm, the authors built a K-Nearest-Neighbor 
classifier, then found and removed the noisy instance which was wrongly predicted by 
the k-NN classifier. This process is repeated iteratively until no more instances need to be 
removed.  
In all previous instance selection studies, few of them, if any, focused on microarray 
dataset. In this study, we introduce a new instance sel ction method (C-loocv) by 
improving ICF algorithm. C-loocv is applied to remove the noisy instance from 
microarray datasets and more reliable data mining results are expected to be mined from 
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the C-loocv refined datasets. 
 
3.6. CLASSIFICATION 
Classification aims to learn how to classify objects into one of a pre-specified set of 
categories or classes. A robust classification method is very important to classify the new 
samples into the correct category efficiently and accurately. There have been lots of 
studies looking for reliable classification methods, a  discussed below.  
Naive Bayesian: Naive Bayesian is a simple probabilistic classifier based on Bayesian’ 
theorem with the (naive) independence assumption. Based on the rule, using the joint 
probabilities of sample observations and classes, the algorithm attempts to estimate the 
conditional probabilities of classes given an observation. 
K-nearest neighbor (K-NN): K-NN is a method for classifying objects based on closest 
training examples in the feature space, which is a type of instance-based learning where 
the function is only approximated locally and all computation is deferred until 
classification. The K-NN classifier is a simple supervised concept learning scheme which 
classifies unseen instances by finding the closest previously observed instances, taking 
note of their classes, and predicting the class for the unseen instance (Cover et al, 1967). 
K-NN is a non-parametric classifier which has been applied to various information 
retrieval problems. K-NN uses an integer parameter K. Given an input x, the algorithms 
finds the K closest training data points to x, and predicts the label of x based on the vote 
of labels of the K points. 
Decision Tree: In data mining and machine learning, a decision tree is a predictive 
model; that is, a mapping from observations about an object to conclusions about its 
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target value. More descriptive names for such tree models are classification tree (discrete 
outcome) or regression tree (continuous outcome). In these tree structures, leaves 
represent classes and branches represent conjunctions of features that lead to those 
classes. Thus, each node corresponds to a sequence of predicates and their values 
appearing on the downward path from the root to it. Each leaf is labeled by a class. To 
predict the class label of an input, a path to a leaf from the root is found depending on the 
value of the predicate at each node that is visited.  
Many classification methods have been derived from decision tree method. ID3 (Iterative 
Dichotomiser 3) is an algorithm used to generate a decision tree (Quinlan 1993). It 
prefers smaller decision trees (simpler theories) over larger ones. However, it does not 
always produce the smallest tree, and is therefore a h uristic. The ID3 algorithm can be 
summarized as follows: (1) Take all unused attributes and count their entropy concerning 
test samples; (2) Choose attribute for which entropy is minimum; (3) Make node 
containing that attribute. 
C4.5 algorithm is an extended version of ID3, which is used to generate a decision 
developed by Ross Quinlan (Quinlan 1993). C4.5 is often referred to as a statistical 
classifier. C4.5 uses the fact that each attribute of he data can be used to make a decision 
that splits the data into smaller subsets. C4.5 examines the normalized information gain 
(difference in entropy) that results from choosing an attribute for splitting the data. The 
attribute with the highest normalized information gain is the one used to make the 
decision.  
Committee decision techniques such as AdaBoost (Freund et al., 1996) and Bagging 
(Breiman et al., 1996) have also been proposed to increase the prediction accuracy by 
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voting the member decisions of the committee. Both AdaBoost and Bagging apply a base 
classifier multiple times to generate a committee of classifiers using bootstrapped training 
data. By the bagging idea, a bootstrapped training set is generated from the original data.  
Boosting uses a different method to construct the committee of classifiers. It builds the 
individual classifier sequentially so that every new classifier is influenced by the 
performance of those built previously. Therefore, the samples incorrectly classified by 
previous models can be emphasized in the new model. 
Classification and Regression Tree (CART): CART (Breiman et al. 1984) are 
nonparametric procedures for explaining and/or predicting a response, either categorical 
(then this is discriminant analysis or classification), or continuous (then this is a 
nonparametric regression).  
Support vector machines (SVM): Support vector machines are a relatively new type of 
learning algorithm. SVMs were originally introduced by Vapnik and co-workers (Boser 
et al., 1992; Vapnik et al., 1998) and successively extended by a number of other 
researchers (Malossini et al., 2000, Cristianini et al., 2000). Recently, SVMs have been 
shown to perform well in multiple areas of biological analysis including evaluating 
microarray expression data (Statnikov et al., 2005, Brown et al., 2000).  
Support vector machines (Vapnik, 1998) have exhibited superb performance in binary 
classification tasks. Intuitively, SVM aims at searching for a hyperplane that separates the 
two classes of data with largest margin (the margin is the distance between the 
hyperplane and the point closest to it). SVMs have demonstrated the ability to not only 
correctly separate entities into appropriate classes, but also to identify instances whose 
established classification is not supported by data. Although SVMs are relatively 
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insensitive to the distribution of training examples in each class, they may still get stuck 
when the class distribution is too skewed. This is obviously not the desired classification 
result.  
Emerging patterns (EPs): EPs (Dong, Li 1999) can also serve as a classification model. 
By aggregating the differentiating power of EPs/JEPs, the constructed classification 
systems (Li et al 2002, Li et al 2001, Dong, Zhang et al 1999) used to be more accurate 
than other previously existing classifiers. In recent years, several new classifiers have 
been generated on the basis of EPs, which will be discussed next. 
Prediction by collective likelihood (PCL): PCL (Li, et al., 2002) is based on the 
concept of emerging patterns. With the discovery of emerging patterns, PCL proceeds to 
calculate a classification score for every class when a test sample is presented; and the 
class with the highest score is predicted. The classification scores are calculated by 
aggregating the frequencies of multiple top-ranked EPs: the committee of patterns and 
their collective discriminating power show strong strength. This method makes higher 
accuracy of prediction for many published microarray gene expression data (Li. et al., 
2003b). 
Highly differentiative gene groups (HDGGs): Based on the previous studies, we 
propose a new concept called HDGGs. HDGGs are the specific emerging patterns whose 
frequency is the highest among the EPs mined from one gene club (Mao & Dong, 2005). 
The classifiers built using HDGGs are called HDGG-based classifiers. Our experiments 
indicate that such classifiers predict the samples in many microarray datasets with very 
high accuracy. In this dissertation, we make considerable contribution for classification 
problem using HDGG-based classifiers. 
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Chapter 4: DISCOVERY AND APPLICATION OF 
HIGHLY DIFFERENTIATIVE GENE GROUPS 
(HDGGS) 
4.1. MOTIVATION  
It is commonly believed that suitable analysis of microarray gene expression profile data 
can lead to better understanding of diseases, and better ways to diagnose and treat 
diseases. To achieve those goals, it is of interest to discover the gene interaction networks, 
and perhaps even pathways, underlying given disease from microarray data.  
Most physiological functions in human body are regulated by multiple genes instead of 
individual genes. With specific diseases, the altertion of some physiological functions 
may be controlled by a group of related genes which are interactive with each other. Such 
groups of genes will be referred to as highly differentiative gene groups (HDGGs). Our 
aim of this chapter is to give methods to find such groups of genes, from datasets 
collected for studying such diseases.  
We note that the discovery of HDGGs is a challenging problem, due to the high 
dimensionality of microarray datasets.  
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4.2. OUR APPROACH 
A highly differentiative gene group (HDGG) is defined as a set of genes which co-
express in a certain manner consistently and frequently in the diseased class but never co-
express in that manner in the normal class, or vice ersa. For example, in Table 4.1, {g4, 
g5} is a HDGG since g4 is low (shown as ‘0’) and g5 is high (shown as ‘1’) in all diseased 
samples, but there are no normal samples where g4 is low and g5 is high. We only want to 
discover minimal HDGGs (in the set-containment sense) to ensure that the set of HDGGs 
is concise. We use frequency of HDGGs in a class to measure their strength, where high 
frequency indicates high strength. When a HDGG has 100% frequency in a class, we call 
the HDGG a signature HDGG for that class.  
Table 4.1: A simple gene expression dataset 
 d1 d2 d3 d4 d5 n1 n2 n3 n4 n5 
g1 1 0 1 1 1 0 0 0 0 0 
g2 0 0 0 1 0 1 1 1 1 0 
g3 1 1 1 1 1 1 0 1 0 1 
g4 0 0 0 0 0 1 1 0 1 0 
g5 1 1 1 1 1 0 1 0 1 0 
d1…d5: diseased tissues; n1 … n5: normal tissues. g1 … 5: genes.  
‘0’: the gene expresses low; ‘1’: the gene expresses high. 
 
Since microarray data have thousands of dimensions, discovering HDGGs is a big 
challenge. Border differential algorithm (Dong et al, 1999; Dong et al., 2005) is applied 
to mine HDGGs. For HDGGs mining, the required search time is exponential in the 
number of dimensions. Thus, exhaustive search of the w ole dataset is impossible. The 
border differential algorithm can effectively handle up to 75 genes for current generation 
PCs, but can not finish in reasonable amount of time for much higher dimensions of 
dataset. In this chapter, we introduce methods that can do much better job given the 
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dimensionality challenge. Our methods are based on the ovel concept of gene club. 
A gene club is a set of genes in which the genes have igh potential to be interactive with 
each other. The total number of genes in a gene club should be big enough to contain 
high frequency HDGGs; at the same time, it shouldn’t be too large for border differential 
algorithm to effectively handle up under current generation PCs. Within in a gene club 
we can (i) efficiently discover signature HDGGs which completely characterize the 
diseased and the normal tissues respectively, (ii) find strongest or near strongest HDGGs 
containing any given genes, and (iii) find much stronger HDGGs than using previous 
methods.  
The main idea of our approach is to select, for each given gene g, a set of genes which are 
highly likely to be interactive with g. We call the set of potentially interactive genes a 
gene club of gene g. We will consider several methods for finding good gene clubs. 
Although the determination of gene clubs share similarities with feature selection, it has 
some new characteristics and it is based on the interaction among genes. 
 
4.3. GENE CLUB FORMATION STRATEGY 
In this section, we discuss four methods for gene club formation: the independent method 
(IN), the iterative method (IT), the divisive and independent method (DIN), and the 
divisive and iterative method (DIT). Then, we show the results obtained from several 
public microarray datasets and discuss the importance of mined HDGGs from the gene 
clubs obtained using these methods. 
Our gene club based methods work as follows: First, for each gene g we find a gene club 
for some desired cardinality k. Second, we apply the border differential algorithm (Dong 
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et al., 1999; Dong et al., 2005) to discover the best EPs containing g from the gene club. 
Finally, we remove the conditions to get the HDGGs. All these methods utilize 
information gain for gene groups.  
4.3.1. Independent gene club formation 
The independent gene club formation method (IN) forms a gene club for a gene g by 
selecting the genes which are independently the most interactive with g. This method is 
based on the notion of combined information gain, defined (for each gene g’) as 
)()',()|'( gInfoGainggInfoGainggInfoGain −=
 
The combined information gain captures how g’ interacts with g with respect to the 
disease under consideration, or how much “help” g’ offers to g w.r.t. the disease. The IN 
method works by first ranking all genes g’ in decreasing InfoGain(g’| g) order, and then 
selecting the k-1 genes g1, g2, …, gk-1 with the highest combined information gain as the 
gene club for g. Figure 4.1 illustrates how the method works; the combined information 
gain is shown as the label for the edge from g to g’, apparently, I1 ≥ I2 ≥ … ≥ Ik-1. 
From Table 2.1, the gene club of size 3 for gene g1 formed by IN consists of g2 and g4, 
since InfoGain(g2|g1) = 0.554 > InfoGain(g4|g1) = 0.502 > InfoGain(gi|g1) for i = 3 or 5.  
g
g1 g2 gk-1…
I1 I2 Ik-1
 
Figure 4.1: the IN method 
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4.3.2. Iterative gene club formation 
The iterative gene club formation method (IT) forms a gene club for a gene g by selecting 
the genes which are iteratively the most interactive with g for a current partial gene club. 
This is different from the IN method, which does not c nsider the interaction of a new 
gene with other selected genes. IT is based on the notion of generalized combined 
information gain, defined (for each gene g’ and select d genes g1,…, gm) as 
,...,(),...,|'( 2121 ggInfoGaingggggInfoGain m = ),,...,()',, 21 ggggInfoGainggg mm −  
The generalized combined information gain captures how g’ interacts with the current 
partial gene club with respect to the disease under consideration, or how much help g’ 
offers to the partial gene club w.r.t. the disease. IT finds a gene club of size k for g as 
follows: First it sets the partial gene club to be {g}; it then selects the next gene g1 having 
the highest InfoGain(g’ | g) among all remaining genes g’ and adds g1 to the partial gene 
club; it then selects the next gene g2 having the highest InfoGain(g’| g1, g) among all 
remaining genes g’ and adds g2 to the partial gene club; it then selects the next g ne g3 
having the highest InfoGain(g’| g1, g2, g) among all remaining genes g’ and add g3 to the 
partial gene club;  this process is repeated until the (k-1)th gene is selected and the partial 
gene club becomes the final gene club of g. Figure 4.2 illustrates the iterative process, 
where the edge labels represent the generalized combined information gain.  
g
g g1
I1 g3
I3g g1
g2
I2 g2g g1 …
 
Figure 4.2: the IT method 
According to the data in Table 2.1, the gene club of g1 formed by IT consists of g2 and g5, 
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which is different from that formed by IN. One can verify that InfoGain(g5| g2, g1) > 
InfoGain(g4| g2, g1). 
 
4.3.3. Divisive gene club formation 
We now turn to two more methods which first divide th  data using a split value for g, 
and then use one of the two previous methods to work with each partition. This is 
illustrated in Figure 4.3. The selected genes from the two partitions are then combined to 
form the overall gene club for g. If IN is used foreach partition, this method is called the 
divisive independent method (DIN); if iterative method is applied, this method is called 
divisive iterative method (DIT). 
g
Independent 
or iterative
Independent 
or iterative
Low Hi
 
Figure 4.3: the divisive method 
We need to combine the genes selected from the two partitions. For both methods, we 
first select 1/3 of the gene club members from each partition among genes with non-zero 
information gain. The final 1/3 (or more if we did not get 1/3 in the last step) is chosen 
from the remaining selected genes from the two partitions. In DIN, the last 1/3 is chosen 
according to the information gain values for the genes from the two partitions. In DIT, 
this is done by normalizing information gain using the partial gene club size. 
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Normalization is used since it is not very meaningful to compare information gain over 
gene groups with large size differences. 
 
4.3.4. Converged gene ranking 
Since there are thousands of genes in one dataset, it i  impractical to establish gene clubs 
for every single gene. A better strategy is to use top k ranked genes as seeds to form gene 
clubs because the top ranked genes have stronger relationship with the specific class. In 
each club, the HDGGs are mined with border differential algorithm. 
As mentioned before, some genes may not be strongly related with the specific disease 
individually, but they are very important for the disease under consideration when they 
combine with other genes. In another word, they are important for the disease under gene 
group based condition instead of individual condition. Therefore, we need to rank the 
genes with new criterion which is based on genes’ participation in high-quality gene 
groups. 
Converged gene ranking is such a method that gives th  genes which are involved in 
HDGGs more frequently a higher rank. After the genes are ranked according to their 
information gain, the converging method is applied to re-rank these genes. The following 
is the algorithm for converged gene ranking: 
(1). Ranking the genes in decreasing information gai order. 
(2). Using all four gene club methods to obtain the high frequency HDGGs (using top 
ranked genes as seeds). In each gene club, the HDGGs with the highest frequency are 
chosen. H is the set of chosen HDGGs. 
(3).Calculating the weight for every gene in each HDGG in H: 
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(4). Re-ranking the genes according to their weight. 
(5). Repeating steps (1) to (4) until the gene rank order reaches steady state. 
As will be seen later, the set of top ranked genes using information gain gene ranking 
method are different from that using converged gene ranking method. Therefore, the 
seeds for gene club formation are also different. With converged gene ranking, we 
discover many high frequency HDGGs which are missed by information gain gene 
ranking method. Therefore, this strategy can be considered as an auxiliary method which 
can help to find higher frequency HDGGs from microar ay datasets. 
 
4.4. BUILDING HIGH ACCURACY HDGG-BASED CLASSIFIERS 
HDGGs can also be used to build classifiers to diagnose diseases with very high accuracy. 
The following pseudo-code describes how to build HDGG-based classifiers. (The 
parameter k can be determined by the user based on the available computation power. In 
this research, we choose k = 20 as its default value unless stated otherwise). The details 
on building HDGG-based classifier can be found in Chapter 6. 
1. Find the top k genes g1, …, gk ranked by information gain; 
2. For each gene gi, find its gene club using the IT method, and then find the strongest 
HDGGs containing gi using border differential algorithm;  
3. Among the mined HDGGs, a total of 2 * k HDGGs are chosen as classifier according 
to our criteria (see below). Among all these chosen HDGGs, k HDGGs are from one 
class whereas the other k HDGGs from the other class; 
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4. For a given test sample T, T’s score in class x(Cx) is calculated according to the 
frequency of each chosen HDGGs in Cx:  ∑
=
=
k
i x
xi
x n
CinHDGGfrequency
CTS
1
)(
_)(  
where nx is the total number of samples in Cx.  
By comparing the scores of T in all classes, T is categorized into the class in which T has 
the highest score. 
 
Criteria for choosing HDGGs: We apply border differential algorithm to obtain plenty 
of HDGGs from gene clubs. Among them, we need to chose the typical HDGGs as 
classifier according to following criteria:  
(1) High HDGG’s frequency, the higher the better. This is the most important one. 
(2) Low gene overlapping in the chosen HDGGs, the lower the better. This strategy is 
called gene diversity. 
(3) Tie breaking. Two or more HDGGs may have the same frequency and same gene 
diversity. We need to make a rule to break the tie. The following are our rules: 
(i). Comparing the length of each HDGG, shorter HDGGs ranks higher; 
(ii). Comparing the gene’s rank between two or more equivalent HDGGs, the HDGGs 
which contain the lowest ranked gene should be ranked lower. This is also called 
“smallest first rule”. For example, two HDGGs {1, 3, 5} and {2, 3, 4}, both have the 
same length of three genes, gene ‘4’ ranks higher than gene ‘5’, so HDGG {2, 3, 4} ranks 
higher than {1, 3, 5}. 
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4.5. RESULTS AND EVALUATION 
We evaluate the effectiveness of our methods in terms of (i) the high-strength HDGGs 
discovered, (ii) the ability to find the strongest HDGGs, (iii) the improvement of strength 
of discovered HDGGs over the top-k gene method, and (iv) the meaningful biological 
functions of our HDGGs compared with previous gene group methods. The experiments 
were conducted on the following datasets: (1) colon ca cer data (Alon et al., 1996), 
which has 2000 genes and 62 tissue samples (22 normal nes and 40 cancer ones); (2) 
prostate cancer data (Singh et al., 2002), which has 12600 genes and 102 tissue samples 
(50 normal ones and 52 cancer ones); (3) breast cancer data (van’t Veer et al 2002), 
which has 24481 genes and 78 tissue samples (44 non-relapse ones and 34 relapse ones); 
(4) ovarian cancer data (Petricoin et al 2002a), which as 15154 genes and 253 tissue 
samples (91 normal ones and 162 tumor ones); (5) leukemia data (Golub, 1999), which 
has 7129 genes and 72 tissue samples (47 ALL and 25 AML).  
 
4.5.1. High strength HDGGs 
Table 4.2 lists the top 10 HDGGs and EPs in diseased ti sues and normal tissues for the 
colon cancer data. The HDGGs can be obtained by removing the high/low signs from the 
EPs. Each number represents a gene, with ‘1’ for the highest ranked gene according to 
the information gain order. The signs of ‘+’ and ‘–’ represent “high” and “low” 
respectively, e.g. ‘1+’ is for “gene 1 is high”, and ‘4-’ is for “gene 4 is low”. We give the 
accession number and description for the genes which oc ur in the HDGGs, and their 
split values in Table 4.8.  
We observe that some of the signature HDGGs involves g nes ranked at 1089. This 
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implies that such genes are very weak for characterizing the cancer by themselves, but 
they can completely characterize the cancer when combined with several other genes.   
Table 4.2: The top 10 HDGGs in diseased (left) and normal tissue  (right) of colon data 
 Emerging patterns Count 
Frequency 
(%) 
 Emerging patterns Count 
Frequency 
(%) 
{1+ 4- 112+ 113+} 40 100 {12- 21- 35+ 40+ 137+ 
254+} 
22 100 
{1+ 4- 113+ 116+} 40 100 {12- 35+ 40+ 71- 137+ 
254+} 
22 100 
{1+ 4- 113+ 221+} 40 100 {20- 21- 35+ 137+ 254+} 22 100 
{1+ 4- 113+ 696+} 40 100 {20- 35+ 71- 137+ 254+} 22 100 
{1+ 108- 112+ 113+} 40 100 {5- 35+ 137+ 177+} 21 95.5 
{1+ 108- 113+ 116+} 40 100 {5- 35+ 137+ 254+} 21 95.5 
{4- 108- 112+ 113+} 40 100 {5- 35+ 137+ 419-} 21 95.5 
{4- 109+ 113+ 700+} 40 100 {5- 137+ 177+ 309+} 21 95.5 
{4- 110+ 112+ 113+} 40 100 {5- 137+ 254+ 309+} 21 95.5 
{4- 112+ 113+ 700+} 40 100 {7- 21- 33+ 35+ 69+} 21 95.5 
 
 
4.5.2. Ability to find top strength HDGGs and improvement of strength 
over top k method 
Experiments showed that our methods can often find the strongest HDGGs, and they can 
find EPs whose frequency is very close to the strongest for cases when our methods 
cannot find the strongest EPs. The experiments are set up as follows: From the colon 
cancer data, we picked the top 75 genes under the information gain rank. (The number 75 
is chosen for reasons discussed in section 4.2) We then use the border differential 
algorithm to exhaustively mine all the EPs in these 75 genes. For each g of these 75 
genes, let SupBEP(g) be the highest frequency (support) of the discovered EPs containing 
g. We then apply the four methods introduced in this chapter, together with the top-k 
method, on these 75 genes, using a gene club size of 20. For each gene g, we check 
whether a given method can find an EP containing g with frequency of SupBEP(g) from 
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the 75 genes. We considered how often each of the methods is able to find the strongest 
EP. 
We first let S consist of the top 75 genes ranked by information gain. The IT method is 
the best, which can find the strongest EPs for about 82.5% of the genes. We also found 
that the average frequency (over the 75 genes) of the strongest EPs found by IT is more 
than 98% of the average support of the strongest EP. In contrast, the top-k method can 
only find the strongest EPs for 32.5% of the genes, and the average frequency of the 
strongest EPs found by that method is about 77% of the average frequency of the 
strongest EPs. The other three of the new methods are lightly worse than IT. Figure 4.4 
shows the performance of all methods in terms of the average frequency of the strongest 
EPs for the top 20 genes. In the figure, EX denotes th  exhaustive method, and GT20 
denotes the top-k method with k = 20.  
 
 
 
 
 
 
 
 
Figure 4.4: Average frequency of strongest EPs found by six methods over top 75 genes 
in colon cancer data 
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performance. Experiments reported in Figure 4.4 show that the new methods improve 
over the top-k method by a large margin. Indeed, the IT method improved the average 
frequency by 47.1% and 29.8% respectively, in diseased tissues and normal tissues, over 
the top-k method. 
We also conducted experiments for gene club size of 35. Every method except EX 
improved. The relative performance of the methods is imilar to the case when the gene 
club size is 20. 
 
4.5.3. From HDGGs to gene functions and disease understanding  
By using our HDGGs based method to group genes, we found that many genes in the 
HDGGs are related to the disease under consideration (i.e. colon cancer in our example). 
Indeed, from the signature HDGGs in Table 4.2, we found several genes have known 
biological functions. For example, in the HDGG {1, 4, 112, 113}, gene 1 (Chang et al., 
2002) has been studied intensively. It is one of the major mediators of the inflammatory 
response and a potent angiogenic factor. There is a close relation between the level of this 
gene and the state of illness: the higher the expression level it is, the more serious the 
patients' condition. Gene 4 encodes a kind of cysteine and glycine-rich protein, which 
may be involved in regulatory processes important for cellular development and 
differentiation (Wang et al., 1992). Gene 112 regulates cell growth; it is believed to have 
some tissue-specific functions, although its specific function is still under study (Nomura 
et al., 1994). Gene 113’s function includes the following: it accelerates differentiation of 
select human hematopoietic cells; it encodes a protein which is a receptor in 
erythropoiesis; it may play a role in angiogenesis (Wang et al., 2002). The fact that {1+, 
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4-, 112+, 113+} is a pattern characterizing the colon diseased tissue is consistent with the 
function of the four involved genes.  
Some genes in HDGGs, especially the low-ranked genes, have not received enough 
investigation. The membership of these genes in HDGGs indicates that these genes are 
important for the disease under consideration.  For example, gene 113, gene 216, gene 
1089 and so on are low-ranked genes. We were not able to find definitive published 
results indicating the function of such genes. We believe that these genes should be 
studied further in the biology and medicine fields.   
The HDGGs may be used to suggest research directions to find gene functions and to 
discover new pathways. Many of the cancers considered in this paper are still the subject 
of extensive research (Sugiyama et al 2005), and the majority of the pathways are still to 
be found in large NIH supported projects (Newcomb 2003). These may be reasons why 
we only found the APC pathway related to colon cancer in the literature and the web, and 
the APC gene (accession number M74088) for this pathw y was not included in the colon 
cancer data. 
We also observed that, for some diseases such as leukemia and lung cancer, our gene 
club methods produced smaller improvement over the top-k approach than for other 
diseases. This happened because the top-k approach has achieved very high average 
support (89% in leukemia and 94% in lung cancer data) lready – there is little room for 
further improvement. Interestingly, this implies that the important gene groups for these 
diseases only involve top ranked genes under the entropy measure. We suggest that this 
might be used as an indication that these diseases have relatively low disease complexity. 
On the other hand, colon and prostate cancers may have igh disease complexity, since 
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there are important gene groups for these diseases that involve genes that are ranked quite 
low under the entropy measure. 
 
4.5.4. Other datasets 
We also conducted experiments on several other datasets.  The results are mostly similar 
to that for the colon cancer data. For the prostate d a, the improvement of the IT method 
over the top-k method is 16.97% in diseased tissues and 35.99% in normal tissues, 
respectively (see Figure 4.5). We list some of the top HDGGs in Table 4.7. For the breast 
cancer data, the improvement of the IT method over th  top-k method is 6.03% and 
14.55% respectively (see Figure 4.6). For the ovarian data, the improvement is 4.41% and 
0.92% respectively (see Figure 4.7).  
 
 
 
 
 
 
 
Figure 4.5: Average frequency of strongest EPs by different me hods for prostate data 
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Figure 4.6: Average frequency of strongest EPs by different me hods for breast cancer 
data 
 
 
 
 
 
 
 
Figure 4.7: Average frequency of strongest EPs by different me hods for ovarian data 
 
4.5.5. Gene ranking by converged method 
We re-ranked the gene by using HDGG-converged method. On average, most datasets 
can reach converged stage within 10 - 20 cycles. Table 4.3 lists the sets of top 20genes 
ranked by information gain and by converged gene raking method using colon cancer 
data.  
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Table 4.3: Top 20 genes using information gain ranking and converged ranking 
 
Ranking order Information gain ranking Converged gene ranking 
1 1670 1422 
2 248 681 
3 492 575 
4 764 1670 
5 1771 1041 
6 624 1923 
7 1041 1581 
8 1422 624 
9 512 1632 
10 1770 174 
11 244 1634 
12 257 764 
13 779 1559 
14 398 257 
15 896 1885 
16 1581 492 
17 1292 248 
18 651 580 
19 1226 1327 
20 42 398 
 
 
In the table, the first column is the gene rank order; the second column is the information 
gain based ranking result and the third column is the result by gene converged ranking 
method. The number in the table is the gene’s index. We notice that 50% of top 20 genes 
of the two methods are different. We use bold-number to mark the shared genes (in both 
top 20 genes of the two methods). The converged ranking is gene group-based, whereas 
information gain ranking is individual gene-based. The experimental results show that 
some important genes for one class are not the top genes in the individual gene based 
rank.  
In colon cancer dataset, the average frequency of top 20 HDGGs obtained by information 
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gain ranking is 71.4% whereas that from converged gene ranking is 89.4%. The average 
frequency increased 18%. Using other microarray gene expression data to compare these 
two ranking methods, we also observed that the average frequency increases in some 
degree (data not shown). 
 
4.5.6. Comparison of HDGGs based classification method with other 
methods 
In this section, we compare our HDGGs-based classifier with other classifiers for 
predicting several published microarray cancer datasets. For a given dataset, if one 
classifier can predict the samples with lower error ate, we say that classifier is more 
robust. The error rate of a classifier is defined as the number of samples in a dataset that 
are incorrectly predicted by the classifier. It is al o called test error rate, which is widely 
used in biomedical fields. 
Table 4.4: The error rates of six classification algorithms 
C4.5 
Datasets HDGGs PCL SVM 
Boosting Bagging Single 
Ovarian 3.4 4 5 5 8 10 
Lung Cancer 2 3 1 27 18 27 
ALL subtypes 4 4 7 14 10 21 
 
Using three public datasets (Ovarian, Lung cancer (Hong et al, 1991) and ALL subtypes) 
which have been partitioned into training and testing sets already, we directly compare 
the classification results produced by our methods and some existing classification 
algorithms. Our method (HDGGs-based) has lower error rate than other algorithms 
(Table 4.4). The numbers shown in the table are the error rate.  There is no testing data in 
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ovarian cancer data, so we used 10-fold cross validation method to estimate the error rate. 
We repeated the 10-fold cross validation method for 10 times, and then got the average of 
error rates for ovarian dataset. Our results indicate that HDGGs can be used to build very 
good classifiers and HDGGs are very important feature for a dataset. 
 
4.6. DISCUSSION OF HDGGS AND FUTURE WORK 
Some other methods do not work for HDGG mining: Since frequent itemsets are anti-
monotone (i.e. all subsets of a frequent itemset are frequent), one may be tempted to think 
that some frequent-item or frequent-itemset based mthods can be used to efficiently find 
the high-frequency EPs and HDGGs. For example, one may remove all the non-frequent 
items and then mine the reduced data set. For example, suppose that we want to find EPs 
whose frequency is at least 70% in the diseased tissues. We can first find the frequent 
items whose frequency is ≥ 70% in the diseased tissues. Then, for each tissue (sample), 
we remove the non-frequent items. The reduced samples will then be used to do border 
differential against the normal tissues.  
Table 4.5: Minimum, maximum and average tuple length in reduced dataset of colon 
data 
Diseased class Normal class Threshold 
% Min Max Avg Min Max Avg 
100 179 179 179 541 541 541 
90 423 534 510 730 835 820 
80 596 943 864 863 1051 1010 
70 705 1196 1075 912 1220 1147 
60 795 1364 1216 982 1362 1267 
50 868 1491 1322 1107 1494 1395 
 
This method will not work for microarray gene expression data, because the reduced data 
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sets will still have very high dimensionality. Table 4.5 lists the maximum, minimum, and 
average length of the reduced tuples for thresholds ranging from 50% to 100%. Observe 
that, even for the threshold of 100%, the average tuple lengths are still 179 and 541 in the 
diseased and normal classes, respectively. Moreover, the method is not desirable since it 
requires the user to give a threshold. 
Duplicated genes: There are thousands of gene probes in one microarray chip. During 
hybridization reaction, many different gene probes may hybridize with one gene 
sequence. These gene probes are called duplicate gene probes though their sequences are 
different. In our data analysis, we only keep one copy and eliminate the rests before gene 
club formation among all duplicated probes.  
The following is our criteria for identifying duplicate (or equivalent) genes: We consider 
two genes g1 and g2 as duplicate genes if (a) InfoGain(g1 | g2) = InfoGain(g2 | g1) = 0, and 
(b) NormMutualInfo(g1, g2) = 100%, where NormMutualInfo = (Entropy(g1) + 
Entropy(g2) – Entropy(g1, g2)) / max (Entropy(g1), Entropy(g2)).  
In the colon cancer dataset, there are 106 genes which have duplicated copies, and the 
total number of duplicated copies is 449 (so 343 of these are removed). Table 4.6 lists the 
duplicated genes among the top 500 genes in colon cancer data (Alon et al., 1996). Each 
row contains a set of genes which are equivalent to each other.  
Table 4.6: Duplicated genes in top 500 gene group of colon data
11     12 
112   117 
168   169   170   171 
369   373   375   377   380   385   394   395   402
371   401 
376   387   388  391 
378   400 
382   383 
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Disease complexity: We also observe that, for some diseases such as leukemia and lung 
cancer, our gene club methods produce smaller improvement over the top-k approach 
than for other diseases. This happens because the top-k approach has achieved very high 
average frequency (89% in leukemia and 94% in lung cancer data) already – there is little 
room for further improvement. Interestingly, this implies that the important gene groups 
for these diseases only involve top ranked genes under the entropy measure. We suggest 
that this might be used as an indication that these di ases have relatively low disease 
complexity. On the other hand, colon and prostate cancers may have high disease 
complexity, since there are important gene groups for these diseases that involve genes 
that are ranked quite low under the entropy measure. 
 
Limitation: It is commonly known that microarray datasets are highly variable. The high 
variability in microarray data may affect the reliability of the discovered HDGGs. 
Therefore, it is necessary to test the effect of variability on our data mining results. In 
Chapters 5-7, we are going to investigate and minimize the effect of variability, and mine 
reliable HDGGs from highly variable microarray datasets. 
 
4.7. APPENDIX 
Table 4.7 lists the top HDGGs in normal and diseased classes in prostate cancer dataset 
(Singh et al., 2002). There are 52 disease samples and 50 normal samples in this dataset. 
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Table 4.7: The top 10 HDGGs in diseased (left) and normal tissues (right) of prostate 
cancer data 
Emerging patterns Count 
Support 
(%) 
 Emerging patterns Count 
Support 
(%) 
{07- 331- 557+ 5011-} 51 98.1 {11- 19- 20+ 41+} 43 86 
{07- 331- 564+ 5011-} 51 98.1 {11- 20+ 41+ 3890+} 43 86 
{07- 331- 708+ 5011-} 51 98.1 {11- 20+ 41+ 122-} 43 86 
{07- 331- 719- 5011-} 51 98.1 {11- 41+ 78-} 43 86 
{07- 557- 657- 5011-} 51 98.1 {19- 41+ 78- 122-} 43 86 
{07- 564+ 657- 713+ 5011-} 51 98.1 {01+ 06- 2002+} 42 84 
{07- 657- 708+ 5011- } 51 98.1 {04- 11- 19- 41+} 42 84 
{07- 657- 719- 5011-} 51 98.1 {04- 11- 41+ 122-} 42 84 
{01- 947- 1271-} 50 96.1 {04- 11- 41+ 3890+} 42 84 
{01- 1271- 2083-} 50 96.1 {04- 18+ 507+ 1937+} 42 84 
 
Table 4.8 is the description of the genes that are involved in HDGGs in colon cancer data. 
We named the genes that are involved in HDGGs discriminating genes (DGs). 
Table 4.8: Description of genes involved in HDGGs in Table 4.2
Gene 
number 
Splitting 
point 
Accession 
number 
Description 
1 59.83 M26383 monocyte-derived neutrophil-activating protein mRNA 
2 1696 M63391 Human desmin gene 
3 379.4 R87126 MYOSIN HEAVY CHAIN, NONMUSCLE (Gallus 
gallus) 
4 842.3 M76378 Human cysteine-rich protein (CRP) gene, xons 5 an 
exon 6 
5 84.88 H08393 COLLAGEN ALPHA 2(XI) CHAIN (Homo sapiens) 
6 230 X12671 Heterogeneous nuclear ribonucleoprotein (hnRNP) core 
protein A1 
7 275 R36977 TRANSCRIPTION FACTOR IIIA 
8 735.8 J02854 MYOSIN REGULATORY LIGHT CHAIN 2 
9 447 M22382 MITOCHONDRIAL MATRIX PROTEIN P1 
10 88.9 J05032 Human aspartyl-tRNA synthetase alpha-2 subunit 
mRNA 
11 1048 M76378 Human cysteine-rich protein (CRP) gene, exons 5 and 6 
12 390.4 M16937 Human homeo box c1 protein, mRNA 
13 400 H40095 MACROPHAGE MIGRATION INHIBITORY 
14 289 U30825 Human splicing factor SRp30c mRNA 
15 334 H43887 COMPLEMENT FACTOR D PRECURSOR 
16 84.2 H51015 H.sapiens mRNA for p cadherin 
17 417.3 X57206 GTP-BINDING NUCLEAR PROTEIN RAN 
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18 494.2 R10066 PROHIBITIN (Homo sapiens) 
19 75.43 T96873 HYPOTHETICAL PROTEIN IN TRPE 3'REGION 
20 2598 T57619 40S RIBOSOMAL PROTEIN S6 (Nicotiana tabacum) 
21 735.6 R84411 SMALL NUCLEAR RIBONUCLEOPROTEIN 
35 58.51 M36634 Human vasoactive intestinal peptide (VIP) mRNA 
40 356.4 R28373 HEMOGLOBIN BETA CHAIN (HUMAN) 
69 97.4 R39209 IMMUNODEFICIENCY VIRUS TYPE I ENHANCER-
BINDING  PROTEIN 2 
71 454.7 H17434 NUCLEOLIN (HUMAN) 
108 3239 Z24727 H.sapiens tropomyosin isoform mRNA, complete CDS 
109 282.3 J03040 SPARC PRECURSOR (HUMAN);contains MSR1 
repetitive element 
110 123.6 K03460 Human alpha-tubulin isotype H2-alph  gene, last exon 
112 99.38 D14812 Human mRNA for ORF 
113 155.5 T51849 TYROSINE-PROTEIN KINASE RECEPTOR ELK 
PRECURSOR 
116 24.29 R49459 TRANSFERRIN RECEPTOR PROTEIN (Homo 
sapiens) 
117 36.63 H49515 SIGNAL RECOGNITION PARTICLE 68 KD 
PROTEIN 
136 189.2 X61118 Human TTG-2 mRNA for a cysteine rich protein with 
LIM motif 
137 26.81 R06601 METALLOTHIONEIN-II (Homo sapiens) 
177 24.6 T40578 40S RIBOSOMAL PROTEIN S6 (Homo sapiens) 
188 147.5 M31303 Human oncoprotein 18 (Op18) gene 
216 31 H66786 ESTROGEN SULFOTRANSFERASE (Bos Taurus) 
254 29.03 H64807 PLACENTAL FOLATE TRANSPORTER (Homo 
sapiens) 
263 373.3 M69135 Human monoamine oxidase B (MAOB) gene, exon 15 
309 1393 H20709 MYOSIN LIGHT CHAIN ALKALI, SMOOTH-
MUSCLE ISOFORM 
696 126.4 M59807 NATURAL KILLER CELLS PROTEIN 4 
PRECURSOR 
700 116.5 H87465 PRE-MRNA SPLICING FACTOR SRP75 (Homo 
sapiens) 
1089 373.5 R80855 MAJOR HISTOCOMPATIBILITY COMPLEX 
ENHANCER-BINDING PROTEIN MAD3 
1261 81.16 M23254 Human Ca2-activated neutral protease large subunit 
(CANP) mRNA 
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Chapter 5: MICROARRAY GENE EXPRESSION 
DATA CONCORDANCE DETECTION 
5.1. MOTIVATION 
The microarray technology has great potential for improving our understanding of 
biological processes, medical conditions and diseases. Often, microarray datasets are 
collected using different microarray platforms (provided by different companies) under 
different conditions in different laboratories. The cross-platform and cross-lab 
concordance of the microarray technology needs to be evaluated before it can be 
successfully and reliably applied in biological/clinical practice.  
It has been realized that different testing methods may cause different concordance 
results. In previous studies, the cross platform and cross lab concordance of microarray 
data has been tested using statistical methods, but not with comparative study yet. In this 
chapter, we will detect the cross platform and cross lab concordance under the 
comparative perspective. 
5.2. OUR APPROACH 
In this chapter, we introduce novel comparative methods for evaluating concordance of 
microarray data collected from different platforms and different laboratories. Our 
methods evaluate this concordance by measuring quality preservation of discriminating 
genes and classifiers. The discriminating genes are the genes that participate in HDGGs, 
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and the classifiers are the HDGG-based classifiers which have been discussed in Chapter 
4. They are used to test the platform/lab concordance u der the comparative perspective. 
Our rationale for classifier/discriminating gene transferability is: Considering that 
microarray datasets are generated from different platforms, if the microarray datasets are 
concordant with each other with respect to discriminating genes or HDGG based 
classifiers, then the knowledge on discriminating genes/HDGG based classifiers gained 
from one platform/lab can be transferred to another platform/lab. This is called 
classifier/discriminating gene transferability. 
We apply classifier transferability to test the degree of classifier-based concordance 
between different platforms/laboratories; we use consistency rate to detect concordance 
(consistency) between the datasets before and after most of the gene-level noise is 
removed; and we also use P-value to quantitatively measure the concordance between 
platforms/laboratories. Conclusions on concordance based on our methods mostly agree 
with previous conclusions obtained using other methods, except the cases involving one 
particular platform. It should be noted that our methods are very general, and can be 
applied when two or more tissue types/classes are available. 
 
5.3. MATERIALS AND METHODS 
5.3.1 Gene expression data 
In this chapter, we evaluate our methodology by using ome microarray gene expression 
data provided by the Microarray Quality Control (MAQC) project in terms of inter-lab 
and cross-platform concordance. We describe the MAQC data briefly below; more details 
can be found in MAQC main paper (Shi et al., 2006). The datasets were generated using 
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more than 10 different platforms in more than 30 different labs. We use the data 
generated using four major platforms (Applied Biosystem(ABI), Affymetrix(AFX), 
Agilent on color array (AG1), and GE Healthcare(GEH)), leading to a total of 12 datasets. 
Among them, AG1 is a fairly new technology compared with the traditional two color 
Agilent platform. 
For each platform, there are three repeated datasets (explained below), each from one of 
three laboratories; this design makes both inter/intra platform comparison possible. More 
specifically, four standard mRNAs are used in each lab/platform combination, which 
implies that biological variation has been eliminated. The four mRNAs are named as A, 
B, C (75%A + 25%B) and D (25%A + 75%B). mRNA A is the universal human 
reference RNA (SUHRR) provided by the Stratagene; ad mRNA B is the ambion human 
brain reference RNA (AHBRR) from the Ambion. While mRNA A and B are primitive, 
mRNA C and D are mixtures of A and B with the proportions given above. In each 
dataset, there are five repeats for each mRNA, givin  rise to a total of 20 chip data. Since 
C contains more A than B whereas D contains more B than A, mRNA A & C are grouped 
into one class, whereas mRNA B & D into the other class; Table 5.1 gives a schematic 
explanation. This division is used in all datasets. 
Table 5.1: MAQC style dataset structure 
 Class 1 Class 2 
 mRNA A mRNA C mRNA B mRNA D 
 t1 . . . t5 t6 . . . t10 t11 . . . t15 t16 . . . t20 
g1                     
…                     
gn                     
 
One MAQC dataset: g1..gn are genes; t1…t20 are tissues; 
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The concordance among laboratories/platforms is tested by comparing the datasets 
generated from these lab-platform combinations. Observe that, all of the datasets from a 
common platform have the same set of genes and RNA samples, and they use the same 
gene IDs and RNA sample IDs to refer to the genes ad s mples. For datasets generated 
from different platforms, the same samples are used but they may use different sets of 
genes.  
 
5.3.2. Discovery of discriminating genes 
One main idea in this chapter is to use the transferability of discriminating genes from 
one dataset to another to evaluate the concordance of two given datasets. Discriminating 
genes are genes which are highly correlated with a class, or genes which participate in 
highly differentiative gene groups (HDGGs). The discriminating genes are transferable 
from one lab/platform combination to another, if the discriminating genes discovered 
from the dataset generated from the first lab/platform combination are highly likely also 
discriminating genes for the dataset generated by the second combination, and vice versa. 
Intuitively speaking, high discriminating-gene transferability implies that one can use 
discriminative knowledge gained in one platform/lab combination in another platform/lab 
combination. In this chapter, we use discriminating patterns that occur in one class but 
never occur in the other class. Such discriminating patterns are referred to as HDGGs 
(Mao & Dong 2005) in data mining studies. HDGGs have been proved to be very useful 
for discovering the inherent distinctions between different classes of data, and they have 
been very useful for building highly accurate classifiers (see Chapter 4). 
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The MAQC data we use have only 20 samples. A very high proportion of HDGGs mined 
from such data contain only one gene. Thus, the HDGGs from MAQC data can be 
considered to be equivalent to highly frequent jumping EPs (JEP), which are defined as 
emerging patterns that appear in one class but never exist in other classes. 
As mentioned in Chapter 4, the genes which are involved in HDGGs (or highly frequent 
JEPs) are considered as discriminating genes. If a JEP involves just one gene, then the 
JEP has a condition of one of the following two forms: “g ≤ v” or “g > v”, where g is a 
gene and v is a value; the condition asks whether gene g’s expression value (in a tissue 
under consideration) is ≤ or > than v. A multi-gene JEP is a set (or conjunctio ) of 
several such conditions; we refer to a JEP with k conditions as a k-gene JEP. Multi-gene 
JEPs capture interactions among genes which only happen in one class but never in the 
other classes. Since many biological functions are regulated by multiple genes, we 
collected the DGs from 2-gene and 3-gene JEPs, besides those from one-gene JEPs. After 
using the entropy-based method (Dougherty et al., 1995) to find the split value for each 
gene, the so-called “iterative gene club formation algorithm” (Mao & Dong, 2005) was 
employed to discover 2-gene and 3-gene JEPs from the two classes of each MAQC 
microarray dataset. We selected the JEPs having 100% frequency in the class they occur, 
so the discriminating genes in such JEPs are frequently involved in discriminative 
interactions among genes.   
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5.3.3. Classifier transferability 
If a classifier built from the two classes in one dataset is applied to predict the sample’s 
class type in another dataset and the prediction accur y is high, and vice versa, the 
classifiers can be transferred between the two datasets. High classifier transferability 
represents high similarity between the two datasets. Since MAQC datasets were derived 
from different labs/platforms, high classifier transferability between pairs of such datasets 
indicates high concordance among these labs/platforms. Thus, classifier transferability is 
a good criterion to test the platforms’ concordance. Intuitively speaking, high classifier 
transferability implies that one can use diagnosis knowledge gained in one platform/lab 
condition to predict what may be happening in another platform/lab condition.  
A classifier is a function (or computer program) for classifying objects without class label 
to one of a pre-specified set of categories or classes. It is trained from data having class 
labels. In terms of microarray data, the goal is to build highly accurate classifiers that 
may be used to predict class membership for new microarray samples. Some selected sets 
of emerging patterns have been used as classifiers to predict new samples in microarray 
data with considerable predicting accuracy (Li, J et al., 2002, Li, Dong et al., 2001, Dong 
et al., 1999). Therefore, JEPs can also act as very good classifiers to test classifier 
transferability.  
Here, discriminating genes (DGs) gathered from one-gene jumping emerging patterns 
(JEP) were exploited as classifier to check the classifier transferability between any given 
dataset pair. We used the DGs to build a voting classifier as follows: For each 
discriminating gene gi, suppose ui is gi's split value such that “gi θ ui” is a one-gene JEP 
(where θ is either ≤ or >), and suppose C1 and C2 are respectively the majority classes of 
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gi's low/high intervals. Then gi can be used as a low-level classifier as follows: for an 
arbitrary tissue T, if T(gi) < ui, then T is predicted to be member of C1; otherwise, T is 
predicted as member of C2. We now have a low-level classifier for each of the DGs. The 
voting classifier’s final decision of T’s membership is reached by the voting result of all 
of the DGs.  
In assessing classifier transferability, for each dataset D (or lab/platform combination) we 
get the discriminating genes as a classifier. Then w  test the classifier on any other 
dataset D’. We use the accuracy of the classifier on D’ as the numerical measure for 
classifier transferability.  
 
5.3.4. Discretized-bin consistency rate between dataset pair 
We also propose another concept called discretized bin consistency rate, or consistency 
rate (CR) to measure the concordance between (datasets generated from different) 
laboratories/platforms. The CR between a given pair of datasets is defined as the 
percentage of binary bits (interval values, where each interval is a bin in entropy-based 
discretization (Dougherty et al., 1995) for the two classes in a given dataset) whose values 
are consistent between the two datasets. For example, in Table 5.2, there are 4 tissues and 
3 genes in each of the datasets D and D’. g2’s expression value in t3 is “0” in D but it is 
“1” in D’. This is the only inconsistency between D and D’; all other corresponding bits 
in matching tissues for matching genes are consistet. The total number of bits in each 
dataset is 4 * 3 = 12, and the number of inconsistent bits is 1. So the consistency rate 
between this dataset pair is 11/12 = 91.7%. 
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Table 5.2: Discretized microarray dataset pair (D & D’) sample 
 D D’ 
 t1 t2 t3 t4 t1 t2 t3 t4 
g1 0 0 1 1 0 0 1 1 
g2 1 1 0 0 1 1 1 0 
g3 0 0 1 1 0 0 1 1 
 
t1…t4: tissues; g1 … g3: genes; ‘0’: the gene expresses low; ‘1’: the gene xpresses high. 
 
As mentioned earlier, discriminating genes have been proven to be of great importance, 
because they contain the most valuable information for classification in each specific 
dataset. Our hypothesis is that working on the discriminating genes may give us more 
accurate as well as useful results for analyzing the relationship between different datasets. 
On the other hand, the expression value of non-discriminating genes may be inherently 
random for biological reasons, and is unimportant or less important for most 
medical/biological studies. When used in concordance analysis, the non-discriminating 
genes may contribute a large proportion of inconsistency. In this study, two methods of 
calculating the consistency rate between a dataset pair are performed and compared, (1) 
one using all genes while (2) the other one using the discriminating genes only.  
 
5.3.5. Calculation of P-value 
Another criterion to check cross lab/platform concordance is P-value; P-value is used to 
measure how much evidence we have against the null hypotheses (which states that there 
is no difference between two given datasets). Small P-values suggest that the null 
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hypothesis is unlikely to be true. Traditionally, researchers will reject a hypothesis if the 
P-value is less than 0.05. Here, the P-value is supposed to quantitatively show how 
similar two given datasets are. If P-value is less than 0.05, the two datasets are considered 
as coming from different populations, i.e. they arenot concordant with each other. We 
calculate the P-value by using the permutation test, which involves the random exchange 
of data between two datasets in order to determine the relationship between them. 
For concordance analysis, we focus on the set of common discriminating genes between 
two given datasets D1 and D2. Using methods discussed earlier, we can find a set of DGs 
from the two classes in D1, and similarly a set of DGs from D2. The genes in both DG 
sets were defined as the common DGs. The rationale for our permutation-based approach 
is: if two given datasets are similar, then a permutation of samples (for identical tissues) 
between them will cause very small change to the set of common DGs. In other words, 
the set of common DGs for the two datasets after th permutation should be very similar 
to the set for the original two datasets. Thus, by comparing the set of common DGs from 
the dataset pair before and after the permutation, we can detect whether the original 
dataset pair is concordant or not. We perform a sequence of permutation tests and get a 
series of sets of common DGs, and use that series to derive the P-value (Note: While a 
large number of common discriminating genes is an indication that the two datasets are 
similar, that number alone cannot give us the confide ce interval, but the P-value would 
be able to do so.)  
More specifically, we did the following: (i) we identified the set of common 
discriminating genes (CGo) from the original dataset pair; (ii) we did the same for the 
dataset pair in the result of random permutations; (iii) we repeated step (ii) m times and 
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got m sets (CG1… CGm) of common DGs; (iv) let F = |CGo|, Fi = | CGo ∩ CGi| these 
numbers (F1…Fm) had a mean value (mu) and standard deviation (sigma); (v) finally, we 
calculated the P-value from ‘F’ , ‘mu’ and ‘sigma’ using Chebyshev inequality and tested 
whether (F) and (F1…Fm) came from the same population. Let f denote the random 
variable of the number of common DGs that occur in CGo. (Observe that F = |CGo ∩CGo|.) We used the Chebyshev inequality to estimate (an upper bound of) the P-value, 
which is a frequently used method (Saw J., 1984), as follows:  
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This estimates the area of the curve in Figure 5.1 where |f-mu| is larger than or equal to 
|F-mu| (i.e. situations where f is more extreme than F), which gives us a confidence 
interval on a given dataset pair’s concordance.  
F
mu  
Figure 5.1: Possible distribution of f after many permutations between a dataset pair 
 
5.3.6. Cross platform comparison 
The concordance of four different platforms (ABI, AFX, AG1 and GEH) is evaluated. 
Essentially the same methods as described above are used, except that, in order to make 
the comparison of data from two platforms meaningful, the common genes used in the 
two platforms should be determined and the gene expression values should also be 
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normalized (see below).  
Gene probe matching: Different platforms may use different gene probes. Thus, we 
need to find the matching genes between different pla forms in order to test their 
concordance. To find matching gene probes, we use Unigene IDs. UniGene has been 
widely used to match genes on different microarrays, nd UniGene IDs are considered to 
be the common gene identifier between platforms (Wang et al., 2005). In this study, 
utilizing UniGene IDs, 16140 common genes are identifi d as being present on all four of 
the analyzed platforms. Gene expression values are averaged in cases where multiple 
probes for a given UniGene ID are present on the chip.
Per-gene baseline adjustment: The gene expression values generated using different 
platforms can not be directly compared because of different labeling methods and 
different probe sequences used which may give rise to variable signals for the same target 
(gene). A per-gene baseline adjustment is performed to normalize these datasets.  
Suppose datasets D1 and D2 share m genes (g0 …gm-1) and n tissues (t0…tn-1). Let V1(gk, tj) 
denote gene gk’s expression value at tissue tj in D1 and V2(gk, tj) denote the same in D2 
where 0 ≤ k < m and 0 ≤ j < n. Define: 
)0|),((, njtgVMaxMaxD jkiki <≤=  
)0|),((, njtgVMinMinD jkiki <≤=  
We use the following formula to generate dataset D1’. 
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A similar formula is applied to V2(gk, tj) to generate dataset D2’, where we exchange the 
subscript 1 with the subscript 2. The concordance between D1 and D2 can be investigated 
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by checking D1’ and D2 (or equivalently D1 and D2’) using classifier transferability, 
consistency rate and P-value, as discussed in previous sections. 
5.3.7. Absolute distance (AD) and artificial data 
For concordance analysis, it is desirable to have a quantitative measure of the amount of 
difference between any two given datasets. Here we define one such measure called 
absolute distance (AD):  
Suppose D and D’ are two datasets which share m genes (g0 …gm-1) and n tissue (t0…tn-1). 
Let V(gi, tj) denote a gene gi’s expression value at tissue tj in dataset D and V’(gi, tj) 
denote the same in D’; let Ri denote gi’s expression value range in D, that is, Ri = 
max(V(gi, tj) | 0 ≤ j < n) – min((V(gi, tj) | 0 ≤ j < n). The absolute distance from D to D’ 
(denoted 'DDAD → ) is: 
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The absolute distance (AD) between D and D’ is defined as:  
2/)( '' DDDD ADADAD →→ +=  
Ri is an important feature for gi in dataset D. For every tissue, V(gi, tj) is in [min((V(gi, tj) 
| 0 ≤ j < n), min((V(gi, tj) | 0 ≤ j < n) + Ri)]. In D, V(gi, tj) varies less than Ri from tissue to 
tissue. If the other dataset D’ is highly concordant with D, then, in every tissue, V’(gi, tj)  
should be equal or very close to V(gi, tj). On the other hand, if D’ is not concordant with 
D, the difference between V(gi, tj) and V’(gi, tj) may be larger than Ri. Thus, the relative 
difference between V(gi, tj) and V’(gi, tj) (normalized by Ri) is a good criterion to define 
absolute distance. 
Apparently, if for every gene gi, if |V(gi, tj) – V’(gi, tj) | = 0, then AD between D and D’ is 
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0, which means that  D and D’ are highly concordant; if |V(gi, tj) – V’(gi, tj) | = Ri, then 
AD between D and D’ is 100%. In this situation, according to our results, the P-value 
between D and D’ is less than 0.01, which means D and D’ are not concordant. Therefore, 
this absolute distance measure can be used to indicate how concordant a dataset pair is, 
from highly concordant to non-concordant.  
In order to evaluate the absolute distance between any dataset pair, we create a series of 
artificial datasets with known absolute distance from a given original dataset. These 
artificial data may serve as benchmarks to identify how far apart the tested dataset pair is. 
The strategy for creating artificial data is as follows: for a given original dataset Dori and 
one known absolute distance ADk, we create the artificial dataset Dmodk which differs 
from Dori by ADk by modifying every gene’s expression value V(gi, tj) in Dori with value 
∆i,j. ∆i,j is randomly chosen and satisfy the following two constraints: 
(i). -Ri ≤∆i,j ≤Ri for gene gi,  
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AD , where Ri is gene gi’s expression range in Dori. 
In this study, 10 artificial datasets (D1…D10) are generated from each Dori. The AD 
between each Dori and the 10 associated Dmodk are 10%, 20%, ….100%, respectively. A 
total of six Dori datasets are used for creating Dmodk. Each of the first four of these Dori 
datasets is constructed from the three repeats of one of the four platforms by averaging as 
follows: For each platform, let Vm(gi, tj) denote the gene expression value of tj n gi in the 
mth repeat of the given platform, and let V(gi, tj) denote the same in the Dori dataset to be 
constructed from the three repeats; then V(gi, tj) = (V1(gi, tj)+ V2(gi, tj) + V3(gi, tj))/3. The 
fifth Dori is obtained by (1) normalizing (as discussed earlir) and (2) averaging the 
expression values of those genes shared by all four platforms of the previous four Dori 
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datasets. The sixth Dori is created randomly, where the “expression value” of each gene at 
each tissue is randomly generated. 
 
5.4. RESULTS 
5.4.1 Concordance test by classifier transferability 
We used classifier transferability to evaluate both cross-lab concordance and cross-
platform concordance.  
For cross-lab concordance, let D and D’ be two datasets respectively generated by two 
laboratories using a common platform. We mined discriminating genes from each of the 
two datasets, say D, and then used them to build a classifier to predict the class of 
samples in the other dataset D’. The classifier’s prediction accuracy is always 100%. This 
means that microarray datasets from different labortories using any of the four given 
platforms as a common platform are highly concordant.  
Next, the same method was applied to test the cross-platform concordance. Table 5.3 
shows the results. The values in the table are the average accuracy achieved by two 
classifiers, each of which was built from data generated in one of the two platforms to 
predict tissue samples generated in the other of the two platforms.  Our results indicate 
that the three platforms (AFX, ABI and GEH) are highly concordant with each other, but 
the AG1 platform is less concordant with the other ree platforms. 
Table 5.3: Classifier transferability between platforms 
 AFX AG1 GEH 
ABI 100% 62.5% 100% 
AFX  62.5% 100% 
AG1   60% 
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5.4.2 Consistency rate (CR) analysis 
In order to figure out the influence of noise to microarray dataset’s concordance, and 
explain the discordant results in previous papers, the consistency rate (CR) is estimated 
before and after the noise genes are removed. As discussed earlier, CR is calculated in 
two ways involving two different sets of genes, where one way uses all genes, and the 
other uses the discriminating genes only. The results are listed in Tables 5.4 and 5.5.  
Table 5.4 shows the consistency rate in intra-platform comparison. If all genes are 
included, the consistency rate is around 75% for any two labs within one platform (left); 
however, if only the discriminating genes are considered, the consistency rate is between 
92% and 98.5% for any dataset pairs (right).  
Table 5.4: Consistency rate between laboratories 
 All genes Discriminating genes 
 L1 vs L2 L1 vs L3 L2 vs L3 L1 vs L2 L1 vs L3 L2 vs L3 
ABI 73.5% 74.6% 73.4% 98.3% 98.2% 98.5% 
AFX 73.5% 74.0% 75.7% 97.9% 97.3% 98.1% 
AG1 79.3% 76.1% 77.0% 98.0% 98.2% 97.0% 
GEH 64.6% 72.6% 66.0% 92.7% 97.3% 92.5% 
 
L1, L2 and L3 are datasets generated from three different laboratories; each entry in the 
table is the consistency rate (CR) between the corresponding laboratory pair 
 
 
Table 5.5 shows the consistency rate in cross-platform comparison by using either all 
genes or discriminating genes only. The discriminating gene-based CR between any 
dataset pair is considerably higher than all-gene-based CR except for cases where AG1 is 
involved. This result is consistent with classifier transferability result in Section 5.4.1. It 
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should be noted that the 50% CR is what would be achieved for a pair of random datasets 
after discretization, which has been confirmed by our experiments. 
Table 5.5: Consistency rate across platforms 
 All genes Discriminating genes 
 AFX AG1 GEH AFX AG1 GEH 
ABI 73.5% 50.0% 69.1% 88.7% 50.4% 83.7% 
AFX  50.0% 69.9%  50.2% 84.1% 
AG1   49.6%   50.4% 
 
Each entry in the table is the consistency rate betwe n a platform pair 
 
5.4.3 Permutation and P-value 
To quantitatively measure the concordance between two platforms/laboratories, P-value 
is calculated directly between the pairs of datasets generated by the two 
platform/laboratories. The results are shown in Tables 5.6 and 5.7. 
Table 5.6: P-value between intra-platform dataset pair 
 L1 vs L2 L1 vs L3 L2 vs L3 
ABI 0.3097 0.3068 0.3950 
AFX 0.5222 0.6449 0.5109 
AG1 0.4099 0.3435 0.3604 
GEH 0.2017 0.3475 0.2102 
 
 
According to the calculated P-values, there is no statistical significance (P > 0.05) 
between different laboratories using a common platform (see Table 5.6), which implies 
that the laboratories are concordant with each other if they use the same platform. The P-
values for the dataset pairs from different platforms are shown in Table 5.7. There is no 
statistical significance between the dataset pairs from platform ABI, AFX and GEH (P > 
0.05), which again implies concordance; however, the dataset from AG1 is significantly 
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different from the other three platforms (P < 0.05), which implies non-concordance. 
Table 5.7: P-value between cross-platform dataset pair 
 
 
 
5.4.4 Absolute distance (AD) as bridge 
It takes much time to calculate reliable P-value directly by permutation due to two 
reasons: (i) In order to get reliable P-value, a fairly large number (at least hundreds) of 
permutations are required. (ii) For each resulting dataset pair from these permutations, we 
need to compute the discriminating genes by examining up to n3 sets of genes, where n is 
the total number of genes. Therefore, to get P-value between a dataset pair directly by 
permutation is not very effective. It will be desirable if we can find an alternative way to 
obtain P-value such as from known consistency rate. In our approach, we use some 
artificial datasets with known degree of absolute distance (AD) to serve as a bridge to 
relate P-value and consistency rate (CR). Ideally we want to have a one-to-one 
correspondence between AD and CR, and between AD and P-value. 
 
A.  Repeatability of artificial datasets 
Since the artificial datasets were created randomly (see Section 5.3.7), for a given AD 
one may create different datasets at different times. This may cast doubt on whether the 
measures and the correlations generated from such artifici l datasets are completely 
repeatable. Therefore, the repeatability of the correlation between AD and CR/P-value 
derived from such artificial datasets needs to be checked. 
 AFX AG1 GEH 
ABI 0.198 0.011 0.201 
AFX  0.012 0.286 
AG1   0.010 
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Six series of artificial datasets from six original datasets are used to check the 
repeatability of the correlation between AD and CR, and between AD and P-value. 
Figures 5.2 and Figure 5.3 show the results. Overall, when discriminating genes were 
used to calculate CR and P-value,  the relationships between AD and CR, and between 
AD and P-value were very reproducible and independent of the dataset used, and the 
correlations were also quite close to a one-to-one correspondence. This is the case despite 
the fact that the six original datasets are very different from each other; in fact, different 
datasets (from different platforms) may use sets of genes, the gene expression value 
ranges vary considerably between datasets, and one of the six original datasets was 
generated randomly.   
The CR between each artificial dataset and its original dataset was calculated. (Recall that 
each artificial dataset was generated from its original dataset for a given AD) Six series 
of artificial datasets produce six CR/AD plots (Figure 5.2). The repeatability of CR/AD 
plots is confirmed by the almost exact overlapping of these plots. The maximum CR 
difference between the six curves is less than 3% at each absolute distance (X-axis). Thus, 
this correlation is considered as very repeatable. 
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Figure 5.2: Correlation between absolute distance and consistecy rate measure, and 
repeatability 
Each curve was generated from one of the six series of artificial datasets. The name of the 
curve corresponds to the Dori of the series of artiicial datasets; CGA in DCGA stands 
for Common Gene Averaging, and RAN in DRAN stands for RANdom. 
 
P-values were calculated by permutation test on the six series of artificial datasets 
described above. Six series of P-value/AD curves are plotted (Figure 5.3). When the AD 
is greater than 60%, the six curves are highly similar to each other. Though there were 
minor differences between P-values in these curves when AD is less than 60%, we are 
still able to draw consistent conclusion regarding the dataset pair concordance (P>0.05). 
Since all P-values were created by random permutation, the more repeats of permutation 
we do, the more reliable the P-value will be. In this study P-values were calculated by 
100 times of random permutations. 
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Figure 5.3: Correlation between absolute distance and P-value, and repeatability 
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Figure 5.4: Consistency rate vs P-value 
 
AD has a near one-to-one correspondence with CR (Figure 5.2), and also good 
correlation with P-value (Figure 5.3). Although the correlation between P-value and CR, 
established using AD,  is not exactly a one-to-one fu ction, AD is still be a valuable way 
to tell us how to link consistency rate and P-value, by means of controlled data 
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modification.  More specifically, from any given CR we can identify a unique AD 
(Figure 5.2), and from each AD value we can identify a small range of P-values. The 
correlation between CR and P-value is plotted in Figure 5.4; Table 5.8 lists the 
correlation in table form for ease of reference. 
This curve can become useful tool for estimating P-value if consistency rate between 
dataset pair is known. First, if a CR is given, the range of the corresponding P-value can 
be estimated using Figure 5.4 (the range is specified by the pink area). For example, 
given a CR of 90% between a dataset pair, the corresponding P-value should be between 
0.15-0.25 (and so this dataset pair is concordant). Second, Figure 5.4 shows that if the CR 
between a dataset pair is lower than 73%, the P-value between that dataset pair is lower 
than 0.05, which implies significant difference, or the dataset pair is not concordant. 
Table 5.8: CR vs P-value 
 
 
 
 
 
 
 
 
C. Accuracy testing of P-value vs CR curve 
To check the accuracy of the CR/P-value plotted in Figure 5.4, the P-values were 
estimated using the CR listed in Tables 5.4 and 5.5. Next, the estimated P-values were 
compared with the actual P-value shown in Tables 5.6 and 5.7. As expected, the results 
P-value 
CR 
Lower bound Higher bound 
97.9% 0.3484 0.4396 
88.4% 0.1476 0.2206 
75.4% 0.0447 0.0515 
66.3% 0.0307 0.0378 
59.7% 0.0200 0.0276 
55.4% 0.0177 0.0267 
52.9% 0.0150 0.0225 
51.9% 0.0129 0.0198 
51.3% 0.0103 0.0184 
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were consistent with each other. This suggested the plot we got is accurate. 
In order to further test the accuracy of the P-value/CR plot, five pairs of datasets are 
created randomly. The CR and P-value between each dataset pair are investigated. 
Moreover, the P-value is estimated from CR using the P-value/CR plot in Figure 5.4. 
Table 5.9 shows the result. One can see that the acual P-value and estimated P-value are 
also matched well, which suggests that the plot in Figure 5.4 is accurate. 
Table 5.9: Comparison of P-value from randomly dataset pairs 
Dataset pairs CR P-value from permutation Derived P-value from CR 
1 58.7% 0.01 0.008 - 0.01 
2 55.5% 0.0093 0.008 - 0.01 
3 92.5% 0.2465 0.019 – 0.270 
4 84.4% 0.1026 0.08 – 0.11 
5 73.7% 0.0483 0.046 – 0.049 
 
 
5.5 DISCUSSION AND CONCLUSION 
In this chapter, three comparative analysis methods were introduced to test the 
microarray datasets’ concordance. These methods were designed for comparative studies 
and focused on discriminating genes in the datasets: cla sifier transferability tests the 
degree of concordance between platforms/laboratories; consistency rate detects 
concordance (consistency) between the datasets before and after most of the gene-level 
noise is removed (each gene value is discretized to have only 0 and 1); and P-value 
quantitatively measures the concordance between platforms/laboratories. In the P-value 
based method, numerous and random permutations between datasets were conducted 
before the concordance decision is made. Analyzing the datasets provided by MAQC 
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project, our results showed that microarray data from different labs within any one of the 
four platforms are fairly concordant at discriminatg gene level; moreover, cross-
platform microarray data derived from ABI, AFX and GEH are also concordant. Our 
methods are fairly general, requiring just two tissue types and can be applied to cases 
with two or more tissue types or classes. 
Our methods have been successfully applied to the datasets with two tissue types. If there 
are more than two tissue types in any given datasets, our methods can still be applied. We 
have two strategies to handle such datasets. (1) We can randomly divide the tissues into 
two classes, and then apply our methods. (2) We can also apply our methods for each pair 
of tissue types in the dataset pair, and combine the results for all tissue type pairs together 
and find out the concordance between the dataset pair. (If there are n tissue types in the 
given dataset, then our methods should be applied n * (n - 1) / 2 times.) Compared with 
the first strategy, this strategy is more accurate, l hough more time consuming. 
Noise exists in microarray data. However, having minor differences doesn’t mean that 
two datasets must be inconsistent. Some studies (Kuo et al., 2002, Kothapalli et al., 2002) 
concluded that the datasets from different platforms are not concordant. They reached 
this conclusion by comparing all genes in the microarray data, without filtering out the 
noise. In our study, we calculated consistency ratebetween dataset pairs from different 
laboratories and different platforms. If all genes were included, we got conclusion that 
the microarray data from different platforms have poor reproducibility. However, when 
only considering discriminating genes for analysis, we found that, besides very high 
concordant rate within platforms, 3 out of 4 platforms are also concordant with each other 
except the AG1 platform.  
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Recent publications derived from the MAQC project used some other methods to 
conclude that all of the 4 platforms are fairly conrdant with each other (Shi et al, 2006, 
Guo et al, 2006). Fold-change ranking with a nonstri gent P-value cutoff method was 
used to rank the genes in these studies. Only the top ranked genes were selected for 
platform-concordance analysis for noise removal. After noise removal from the 
microarray datasets, it was found that the microarray datasets from different 
laboratories/platforms are fairly concordant. 
Guo and colleagues also noticed the importance of discriminating genes in concordance 
evaluation, although they used the fold change method o discover DGs. It should be 
pointed out that the fold change method uses ratio of average of values in the two classes, 
whereas the entropy-based method aims to find splitva ues to separate the classes as 
cleanly as possible. So their criteria for discriminat ng gene selection are very different 
from ours. We believe that the entropy-based discriminating gene selection method used 
in this paper is more biological meaningful. Instead of arbitrarily selecting highly 
differentially expressed genes, we selected the genes that participate in discriminating 
gene groups; such groups are highly related to one of the classes in the dataset. Thus, 
these selected genes may provide insights on gene interaction networks, or even 
pathways for the specific disease. Moreover, the entropy based method (Dougherty et al., 
1995) has been widely used in the data mining and machine learning communities (Han et 
al, 2006). 
It was realized that different gene selection criteria led to different concordance results. 
Guo et al used six different gene selection methods t  choose and rank genes. They got 
different concordance results from their different gene selection methods. In this study, 
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we used comparative methods to select discriminating genes for platform concordance 
testing. Compared with their results, we reached the same conclusion that the datasets 
within a given platform are highly concordant, and that the non-AG1 platforms are fairly 
concordant with each other. However, we assessed that the AG1 platform has low 
concordance with other platforms according to the datasets provided by MAQC project, 
whereas Guo et al concluded that the AG1 platform is also concordant with other 
platforms. While the agreement results reinforce prvious results and indicate that most 
platforms are concordant with each other, the disagreement was the results of using 
different gene selecting and testing methods. 
Our conclusion can be helpful for the future comparative studies. For example, since 
AG1 and other platforms are not concordant under comparative discriminating gene 
selection, the datasets from AG1 can’t be analyzed together with the datasets from other 
platforms in comparative studies, such as discriminating gene data mining. On the 
contrary, these datasets can be analyzed together under fold-change ranking with a 
nonstringent P-value cutoff method. 
It should be noted that, the concordance results report d in this paper were based on 
datasets from MAQC, which were derived from well contr lled experiments and identical 
reference RNAs. In real world situations one also needs to consider lab-practice 
variability and biological variability, which will be discussed in Chapter 6. 
5.6 APPENDIX 
Since discriminating genes play a key role in microar ay dataset, it is tempting to use the 
percentage of number of common discriminating genes (which we refer to this approach 
as the basic discriminating gene transferability) to directly measure the concordance 
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between a dataset pair, or to use the binning cut-point difference of common 
discriminating genes to test the concordance. If one r both of these two methods can 
serve as such a measure, the concordance between a dataset pair can be easily determined. 
Unfortunately, none of these methods work for microar ay gene expression data, because 
for concordance determination, both methods are sufficient condition, but not necessary 
condition. In other words, two datasets with a small number of common discriminating 
genes or with a large cut-point difference may still be highly concordant.  
We created four datasets pairs with controlled degre  of concordance to test the above 
two methods. Dk and Dk’ is one dataset pair, where 0<k≤4; Nk is the number of 
discriminating genes in dataset Dk; Nk’ is the number of discriminating genes in dataset 
Dk’; Ck is the number of common discriminating gene in both Dk and Dk’. The CDG 
Ratio (common discriminating gene ratio which is mined using basic discriminating gene 
transferability) between one dataset pair is calculted by the following formula:   
CDG ratiok = (Ck * 2) / (Nk + Nk’) * 100%. 
The CP Diff (cut point difference) is calculated as the following: 
%100*/))/|)()((|(
1
0
' nRcVcVDiffCP ki
n
i
ikikk ∑−
=
−=  
where Vk(Ci) and Vk’(C i) denote gene gi’s cut point at dataset pair k, and Ri is gi’s 
expression value range. The testing results are shown in Table 5.10. 
Table 5.10: Comparison of dataset concordance using different methods 
Dataset 
 pairs 
CP 
diff 
CDG Ratio 
Classifier 
transferability 
Consistency 
rate 
P-value 
1 17.0% 81.6% 100% 99.5% 0.6563 
2 17.8% 71.3% 82.5% 89.4% 0.1326 
3 17.3% 72.2% 74.0% 78.6% 0.0527 
4 18.2% 52.8% 50.5% 52.5% 0.0082 
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Four pairs of datasets were created in a controlled manner: dataset pair 1 is highly 
concordant between each other; dataset pair 2 is concordant; dataset pair 3 is on the 
boundary of concordance and dataset pair 4 is not concordant. 
 
In Table 5.10, besides cut-point difference and CDG Ratio, the classifier transferability, 
CR and P-value result are also listed for comparison. According to the table, classifier 
transferability, CR and P-value can act as very good criteria to scale the concordance 
between dataset pair, but cut point difference and CDG ratio can’t. 
The following are weakness of these two methods. Suppose there are m tissues in dataset 
D. So each gene gi has m expression values in D. (1) the basic discriminating gene 
transferability uses the number of common discriminating genes as criterion. For any 
discriminating gene gi, if its expression value at one tissue is slightly modified so that it 
crosses the old binning cut point, then this gene might not be a discriminating gene 
anymore. Thus, one expression modification in one tissue may affect the whole gene’s 
property, which makes this method very vulnerable. (2) gi’s cut point is highly dictated 
by the two expression values which are closet to the cut point and which envelope the cut 
point So the cut point difference between dataset pair is mostly dictated by those two 
expression values of gi and is insensitive to the others. Thus, it can’t represent the 
behavior of gi, and it can’t serve as an indicator for concordance test either. 
Our analysis of the data on these two methods also indicated the following interesting 
observations: (1) most consistent genes between a dataset pair are discriminating genes. 
(2) Consistency rate for non-discriminating genes is positively correlated to the 
consistency rate for discriminating genes, although the consistency rate for the former is 
much lower than the latter.  
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Chapter 6: MINIMIZING VARIABILITY OF 
MICROARRAY DATASETS  
6.1. MOTIVATION 
During comparative microarray data mining, it is very important to get reliable patterns 
and models in order to gain high-quality understanding the mechanism of specific 
diseases. It has been well known that there is variability in microarray datasets and the 
variability may affect the data mining results. So far, few reports, if any, used 
comparative methods to study this topic. In this chapter, we investigate the effect of 
variability, develop novel methods to reduce the variability, and improve the reliability of 
the mined patterns and models. 
 
6.2. OVERVIEW 
Ideally, if there were no variability in microarray datasets, the mined patterns and models 
should represent the intrinsic features of the classes they belong to. They should be 
independent of the chosen patient samples, laboratories and platforms which were used to 
generate the microarray datasets. Roughly speaking: 
• Data mining results from multiple microarray datases concerning a common 
disease should be identical or highly similar; 
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• Data mining results from different subsets of one microarray dataset should be 
identical or highly similar. 
Unfortunately, variability exists in microarray datasets. Such variability includes 
measurement variability, biological variation and so on (Chapter 2, Section 2.2). 
Microarray datasets are generated from different labor tories using different platforms. 
Experimental noise exists during the data generation of microarray experiments, which 
might cause inconsistent results and produce measurment variability. We have tested 
this effect of experimental noise in Chapter 5. Our results showed that, at comparative 
level, the datasets from a common platform, different labs are highly concordant. 
At the same time, microarray datasets are typically generated using tissue samples from 
different patients. These patients have different characteristics such as height, weight, age, 
race, sex etc. These differences inevitably lead to biological variations in the microarray 
datasets and may affect data mining results and conclusions. Compared with 
measurement variability, which randomly distributes through the datasets, biological 
variation is sample specific. Some samples may bring h gh degree of biological variation 
to the dataset and thus influence the data mining results. 
In this chapter, we consider how to test and minimize the variability by identifying and 
eliminating noisy tissue samples from datasets. The noisy samples may have high degree 
of biological variation, or they may have high degree of measurement variability.  
More specifically, first we use four measurements to evaluate the degree of variability. 
Then we develop a novel method which is called Converged Leave-One-Out-Cross 
Validation (C-loocv) to identify and remove the samples which have high degree of the 
variability in microarray datasets. This process is called biological variability 
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minimization (BVM). Next we compare the data mining results from the original datasets 
with those from the C-loocv refined datasets. And fi ally we show the advantage of C-
loocv application in classification. 
 
6.3. MATERIALS AND METHODS 
6.3.1. Microarray datasets for variability evaluation 
In this chapter, two microarray datasets which study l ng cancer will be used to evaluate 
the effect of variability on our data mining result. These two datasets were generated in 
different laboratories. One dataset was created by Bhattachariee and colleagues 
(Bhattacharjee et al, 2001) in Harvard medical school, which is called Harvard lung 
cancer dataset or Harvard in this study. The other on  was created by Beer and colleagues 
(Beer et al, 2002) in University of Michigan, which is named Michigan lung cancer 
dataset, or Michigan in this study. Both datasets study lung cancer using samples from 
different patients. These two datasets made it possible to check the influence of 
variability on the data mining results.  
There are totally 12,600 DNA probes (genes) and 203 samples in Harvard microarray 
dataset. 17 samples come from normal lung (Normal), and the other 186 samples are 
from lung cancer patients (Tumor). These tumor samples are further divided into five 
subtypes: (1) lung adenocarcinomas (n = 127); (2) squamous cell lung carcinomas (n = 
21); (3) pulmonary carcinoids (n = 20); (4) small-ce l lung carcinomas (n = 6) and (5) 
Other adenocarcinomas (n = 12). In our study, all tissue samples in five tumor subtypes 
are considered as lung cancer samples and categorizd in one group. Thus, there are two 
classes in this dataset: Normal class (n = 17) and Tumor class (n = 186). 
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Compared with Harvard dataset, Michigan dataset is relatively smaller in size and 
simpler in structure. There are 7129 gene probes and 96 samples in Michigan dataset. 
Among 96 samples, 10 of them come from normal controls; the other 86 samples are 
from lung cancer patients. These cancer samples are eparated into two subgroups: 67 are 
stage I and 19 are stage III lung cancer. Same as Harvard dataset, in our study, the cancer 
samples from two subgroups are categorized into one class. So there are also two classes 
in Michigan dataset: Normal class (n = 10) and Tumor class (n = 86). 
Even though both lung cancer datasets were created using a common platform 
(Affymetrix), the total number and the order of gene probes on the two chips are different. 
Thus, the common genes between these two datasets should be identified. Same as 
Chapter 5, we will use UniGene IDs to identify the common genes between these two 
datasets. Gene expression values are averaged in cases where multiple probes for a given 
UniGene ID are present on the chip. 
Because variability in microarray datasets includes measurement variability and 
biological variation, it is desirable to test the effect of measurement variability and 
biological variation separately. MAQC datasets make it possible. The details about 
MAQC data structure have been introduced in Chapter 5. Since all MAQC datasets use 
same mRNA as tissue samples, biological variation is supposed to have been eliminated. 
Thus, MAQC datasets should be very appropriate to test the effect of variability caused 
only by measurement variability. 
6.3.2. Measurements of the degree of variability 
It is difficult to measure the degree of variability n microarray datasets directly. So far, 
no study has been reported to define the degree of variability in microarray datasets; as a 
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result, no attempt has been made to measure it. Here, we define the degree of variability 
between datasets (see note below) as the similarity of data mining results mined from 
such microarray datasets. High degree of variability produces low similarity of data 
mining results, and vice versa. 
In this chapter, we measure the similarity of data mining results mined from microarray 
datasets to evaluate the degree of variability. Roughly speaking, agreements on each of 
the following four types of data mining results obtained from datasets will be used to 
evaluate the degree of variability, (1) the sets of top 20 ranked genes from each dataset; 
(2) classifier transferability (CT) between datasets; (3) the sets of discriminating genes 
(DGs); and (4) the sets of top frequency HDGGs.  
More specifically, first, we rank the genes in each dataset in decreasing information gain 
order and obtain the top 20 gene sets from each dataset. Meanwhile, we discover highly 
differentiative gene groups (HDGGs) from each dataset by using “iterative gene club 
formation algorithm” (Mao & Dong, 2005) and border differential algorithm (Dong et al, 
1999). Recall that genes involved in HDGGs are discriminating genes. 
Next, the similarity of the top gene sets between datasets is evaluated using Jaccard 
similarity coefficient (JSC). Identical criteria are also used to measure the similarity of 
DG sets and HDGGs sets. The Jaccard similarity coeffi ient (JSC) is calculated to check 
the similarity of two sets, which is defined as thesize of the intersection divided by the 
size of union of the sample sets. Thus, the range of JSC is [0, 1]. 
Finally, the discriminating genes from each dataset r  used as classifier to test classifier 
transferability between datasets. (Details about classifier transferability have been 
described in Chapter 5). The range of classifier transferability (CT) is [50%, 100%]. 
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Note: the term “datasets” used in this chapter means the datasets which study a common 
disease. Such datasets are suitable for analyzing the degree of variability. If only one 
microarray dataset is under consideration, we make sev ral subsets by randomly choosing 
samples from each class in this dataset. These subset  are used as “datasets” for 
variability analysis. 
6.3.3. Converged Leave-One-Out Cross-Validation algorithm (C-loocv) 
In microarray datasets, the tissue samples come from a variety of patients. Some samples 
may be highly different from the others in the same class. These noisy samples cause 
high degree of variability and should be eliminated from microarray datasets. Liu and 
colleagues (Liu et al, 2001) developed a so-called ICF algorithm to eliminate noisy 
samples from datasets. In this study, we develop a new algorithm (C-loocv) by improving 
Liu’s algorithm and apply it on microarray datasets. C-loocv is created by combining 
leave-one-out cross validation algorithm with our HDGG-based classifiers. In our 
microarray datasets, C-loocv will be applied to identify and eliminate noisy samples. 
 
A. Leave-One-Out-Cross-Validation (LOOCV) 
Leave-one-out cross-validation (LOOCV) has received much attention since it has been 
shown to give an almost unbiased estimator of the generalization properties of statistical 
models, and therefore provides a sensible criterion for model selection and comparison.  
The original purpose of LOOCV is to compare the robustness of classifiers. In a given 
dataset, one test sample (an unobserved output value ‘y’) is left out and the other samples 
(an observed vector ‘x’) are used to train the classifiers. The trained classifiers are 
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applied to predict ‘y’. The classifiers with better predicting accuracy are considered as 
more robust. Whenever a new classifier is developed, LOOCV is a common method to 
test this classifier’s robustness by comparing with other classifiers. 
During classifier’s robustness comparison, it has been noticed that in some datasets, 
several specific samples could not be predicted corre tly no matter which classifiers were 
applied. This fact led us to consider the reliability of the dataset itself other than that of 
the classifiers. 
As mentioned before, many factors, such as biological variation, high risk normal 
controls, misdiagnosis patients and so on, may cause the test samples to be categorized 
into the incorrect class during microarray dataset generation. According to this fact, we 
will develop algorithms to identify and remove those wrong-predicted samples from 
datasets in order to improve reliability. 
 
B. Building high accuracy HDGG-based classifiers 
HDGG-based classifiers have shown improvement in predicting accuracy over the other 
classifiers. The algorithm for building HDGG-based classifier was mentioned in Chapter 
4. Here, we discuss in detail how to build this classifier. 
Suppose a cancer related microarray dataset D has n tissue samples (t0…tn-1). These 
samples can be divided into two classes according to its class type: “Normal” class CN 
which has n1 samples, and “Tumor” class CT which has n2 samples; the HDGGs are 
mined from CN and CT and will be used to build a HDGG-based classifier. L t’s denote 
the ranked tumor HDGGs in CT as HDGG
T
1, HDGG
T
2 … HDGG
T
x in descending order 
of their frequency in CT. Similarly, denote the ranked normal HDGGs in CN as HDGG
N
1, 
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HDGGN2 … HDGG
N
y also in descending order of their frequency. Next, some normal 
HDGGs and tumor HDGGs are chosen to build a classifier with gene diversity strategy as 
mentioned in Chapter 4, i.e. each discriminating gene occurs no more than once in the 
chosen HDGGs. For example, if one discriminating gene ‘g’ appears in HDGGT1, then all 
other HDGGTs which contain ‘g’ are not allowed to serve in theclassifier. 
 
Suppose the following are the HDGGs selected for use in the classifier, using the gene 
diversity strategy:  
Tumor class (CT): HDGG
T
x1, HDGG
T
x2…HDGG
T
xi, where x1<x2<xi≤x 
Normal class (CN): HDGG
N
y1, HDGG
N
y2…HDGG
N
yj, where y1<y2<yj≤y 
 
In order to predict the class type of a test sample T, the score of the class label of T needs 
to be calculated. Suppose we use k (k < i and k < j) top-ranked HDGGs from CT and CN 
in the scoring process. Then we define the score of T in the CT class as 
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Finally, the test sample T’s score is: score(T) = S(T)_CT – S(T)_CN.  
According to the formula, one can see that for any sample T, -1 ≤ score(T) ≤ 1. If score(T) 
> 0, then sample T is predicted as tumor; if score(T) < 0, then T is predicted as normal; 
score(T) = 0 means we have a tie and T’s class is diff cult to decide. If score(T) is close 
to 1 or -1, T typically belongs to the corresponding class (Tumor or Normal). 
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The parameter k can be determined by the user based on the available computation power. 
In this research, in order to obtain the maximum information from the training datasets 
and make the classifiers as diversity as possible, we keep the number of HDGGs in 
classifiers as large as possible. Thus, in this study, k = i (if i < j), or k = j (if j < i); in 
other words, k is the minimum of the numbers of top-ranked HDGGs for the two classes. 
 
C. The Converged loocv (C-loocv) Algorithm: 
The C-loocv algorithm is designed to identify noisy samples by comparing each testing 
sample’s score using HDGG-based classifiers. This design requires that the scores from 
every sample (T) be comparable. We modify the definition of score(T) in order to fit the 
C-Loocv algorithm:  
For any sample ti, if ti’s original class is “Tumor”, the score of ti is defined as:   
score(ti) = S(ti)_CT – S(ti)_CN 
Otherwise, if t’s original class type is “Normal”, then:  
score(ti) = S(ti)_CN - S(ti)_CT 
This modification ensures that tumor samples and normal samples can be compared 
together.  
The following is C-loocv algorithm. 
Suppose the given cancer related microarray dataset D has n tissue samples (t0…tn-1). 
Step 1: Every sample ti in D is separated as test sample (so the rest are used as training 
samples); this yields a score(ti); 
Step 2: Rank the samples in descending order of their scores; 
Step 3: Remove the samples whose scores are less than threshold τ; 
 88 
Step 4: In the remaining samples, repeat steps 1 to 3 until every sample’s score is larger 
than τ. Now the “core dataset” is obtained; 
Step 5: Use the core dataset as training data to build classifiers and to predict the 
discarded samples in step 3 and rank them in descending order; 
Step 6: Restore the samples whose scores are largerthan τ, and permanently discard the 
samples whose scores are less than τ. Suppose the number of discarded samples is n1, 
then the number of remaining samples in D is n – n1; 
Step 7: Repeat steps 1 to 6 on D until the dataset reaches steady state, i.e. no more 
samples are added or removed; we have now reached the converged state. 
In this study, the threshold τ is set to 0. We can adjust the threshold in order to find the 
best optimization for any given datasets. According to score(T)’s formula, if τ is set 
larger than 0, then some test samples which weakly be ong to their class are also 
discarded; if  τ is set less than 0, the test samples which are slightly predicted wrong are 
kept in the dataset.  
 
6.4. RESULTS OF EVALUATING OUR METHOD 
As mentioned before, four measurements are used her to test the degree of variability in 
datasets. We focus on two measurements: one is the se s of top 20 genes, the other one is 
classifier transferability (CT). The other two measurements (sets of discriminating genes 
(DGs) and sets of HDGGs) are used as reference. 
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6.4.1. Degree of measurement variability 
Since variability includes measurement variability and biological variation, it is desirable 
to test measurement variability alone. According to MAQC style dataset structure, there 
is no biological variation in MQAC datasets. Thus, we can test the degree of variability 
caused only by measurement variability using these datasets. 
Two datasets (ABI_L1 and ABI_L2) from ABI platform are chosen. Using entropy-based 
gene ranking method, several thousands of genes have equally information gain and can 
be ranked as top genes simultaneously. We further re-rank these top ranked genes 
according to their gene index number in their respectiv  datasets (small index number 
ranks higher). Table 6.1 shows the top 20 genes from each dataset. 
Table 6.1: Top 20 genes in two datasets generated with ABI platform 
Rank order ABI_L1 ABI_L2 
1 1 1 
2 4 4 
3 5 5 
4 6 6 
5 7 7 
6 10 10 
7 15 13 
8 16 16 
9 17 17 
10 18 18 
11 24 24 
12 26 26 
13 27 27 
14 31 31 
15 33 33 
16 34 34 
17 37 37 
18 44 39 
19 47 42 
20 55 44 
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According to Table 6.1, we notice that the sets of top 20 genes from two datasets are 
quite similar. 85% of genes in the top 20 gene sets are identical (bold font). The Jaccard 
similarity coefficient (JSC) between these two sets is 0.739.  
Classifier transferability (CT) between these two datasets is also calculated: CT = 100%. 
We also calculate the JSC value from the sets of DGs and the sets of HDGGs. JSC = 
0.676.  
According to these results, we conclude that measurment variability exists in the 
datasets and moderately affect the top 20 gene ranking. But it has no effect on classifier 
transferability. This is consistent with the result in Chapter 5. 
 
6.4.2. Artificial dataset with maximal degree of variability 
In Section 6.4.1, we tested our measurements using MAQC datasets which have minimal 
degree of variability (no biological variation). We also need to test our measurements 
with the datasets which have maximal degree of variability. Clearly, for any two datasets, 
if JSC = 0 and CT = 50%, then the degree of variability in those datasets is maximal.  
In order to obtain such datasets, we randomly swap several samples between two classes 
in one dataset. In ABI_L1 dataset, we exchange several samples in t1 … t10 with the 
corresponding samples in t11 … t20 (see Table 5.1). After sample swap, the modified 
dataset is named as ABI_L1’. Top 20 genes are ranked from two datasets (ABI_L1 and 
ABI_L1’). As expected, there is no common gene shared by the two sets of top 20 genes 
(JSC = 0 and CT = 50%). In fact, after we exchange only four samples (t1 vs t11and t2 vs 
t12), we have gotten maximal degree of variability. The top 20 genes in both sets have 
already become completely different (Table 6.2). 
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Table 6.2: Top 20 genes before vs after sample swap 
Rank order ABI_L1 ABI_L1’  
1 1 11535 
2 4 441 
3 5 500 
4 6 580 
5 7 666 
6 10 694 
7 15 792 
8 16 1086 
9 17 1334 
10 18 1381 
11 24 1550 
12 26 1565 
13 27 1669 
14 31 1711 
15 33 1802 
16 34 1828 
17 37 1942 
18 44 2277 
19 47 2809 
20 55 2882 
 
In Table 6.2, the second column is the top 20 genes from original ABI_L1 dataset. The 
third column is the top 20 genes from dataset ABI_L1’, in which two pair of samples are 
swapped. 
We use our C-loocv algorithm to identify noisy samples from ABI_L1’. These swapped 
samples can easily be identified and eliminated. After noisy sample removal, the data 
mining results from the refined datasets become highly consistent. 
 
6.4.3. Variability in lung cancer datasets  
As mentioned before, both Harvard and Michigan datasets study lung cancer and both of 
them were generated using the Affymetrix platform. We have proved that datasets 
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without biological variation, which come from a common platform and different 
laboratories, are highly concordant (see Chapter 5). Thus, if no biological variation exists 
in the two lung cancer datasets, the top 20 gene sets from both datasets should be 
identical or very similar, and classifier transferability (CT) between these two datasets 
should be 100% (see Section 6.4.1). 
Top 20 gene sets: Table 6.3 shows the sets of top 20 genes mined from Harvard and 
Michigan datasets. The number in the table is the gene’s index number, i.e, each number 
represents one specific gene. 
Table 6.3: Top 20 genes in Harvard and Michigan lung cancer dataset 
Rank order Michigan Harvard 
1 845 2910 
2 1344 640 
3 1814 2688 
4 2040 2607 
5 2910 4351 
6 3895 5180 
7 711 3284 
8 2275 845 
9 2607 1344 
10 2688 2555 
11 3581 1981 
12 3945 3895 
13 4020 3911 
14 4145 4598 
15 3136 2956 
16 223 123 
17 997 1814 
18 2287 3945 
19 2508 4657 
20 2736 4165 
 
The top 20 genes from the two datasets are not very similar. Only 40% of the genes are 
shared in both gene sets. We use bold-number to mark the common genes in both top 20 
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genes from two datasets. The JSCtop20 is equal to 0.25. The rankings of some specific 
genes differ greatly between two datasets. For example, gene 2040 ranks top 4 in 
Michigan, but ranks very low (top 91) in Harvard. We also mined the HDGGs and 
discriminating genes (DGs) from both datasets. The JSCDG is equal to 0.184, and 
JSCHDGG is equal to 0.056 between Michigan and Harvard datasets. The details about the 
sets of DGs and the sets of HDGGs are listed in Section 6.6, Table 6.6 and Table 6.7. 
 
Classifier transferability: CT between two datasets is not very high. When Harvard 
dataset is used to build HDGG-based classifier to test he tissue samples in Michigan 
dataset, the predicting accuracy is 55.2%. When Michigan dataset is used to build 
HDGG-based classifier and predict Harvard dataset, th  accuracy is 83.6%. Therefore, 
the classifier transferability (CT) between Harvard nd Michigan datasets is CT = (55.2% 
+ 83.6%) / 2 = 69.4%. 
These inconsistent data mining results indicate that there is high degree of variability in 
Michigan and/or Harvard datasets. Therefore, we will m nimize the variability in next 
section. 
 
6.4.4. Biological variability minimization (BVM) 
Both Michigan and Harvard datasets are treated with C-loocv in order to find and remove 
the noisy samples. It takes less than 10 cycles before the datasets reach steady state. After 
C-loocv processing, the new datasets are named as refined (Michigan/Harvard) datasets. 
In contrast, before C-loocv, the datasets are called original datasets. 
Several samples are removed by C-loocv. In Michigan, 5 samples are eliminated. These 
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samples include 3 tumor samples (stage I lung cancer, patient number 16, 19 and 54) and 
2 normal samples (patient number 88 and 90). In Harvard, 13 samples are eliminated. 
They are 10 tumor samples (patient 15, 17, 21, 76, 83, 117, 121, 132, 135 and 137) and 3 
normal samples (patient number 193, 199 and 203). After BVM, there are 91 samples in 
refined Michigan dataset and 190 samples in refined Harvard dataset.  
 
JSC from refined datasets: Top 20 genes are mined from both refined datasets. The 
results show in Table 6.4.  
Table 6.4: Top 20 genes in refined Harvard and Michigan lung cancer datasets 
Rank order Michigan Harvard 
1 711 640 
2 845 845 
3 1344 1344 
4 1814 2607 
5 2040 2688 
6 2275 2910 
7 2287 4351 
8 2607 2555 
9 2910 3895 
10 3136 2956 
11 3581 3197 
12 3895 3284 
13 4020 123 
14 5269 1814 
15 123 1981 
16 1981 1241 
17 2555 3911 
18 2688 4704 
19 3945 2916 
20 2956 3945 
 
The similarity of data mining results from the two refined datasets is improved. 60% of 
the genes appears in both top 20 genes sets (bold font) and JSC(top20, BVM) = 0.43. Recall 
 95 
that before BVM, JSCtop20 = 0.25. We also compare sets of top 40, top 60 and top 80 
genes from both datasets before and after BVM. All of them show that after BVM, the 
Jaccard similarity coefficient value increases. We test the discriminating gene sets and 
HDGG sets too. After BVM, the number of common genes in both discriminating gene 
sets and HDGG sets also increased. JSC(DG, BVM) = 0.40 and JSC(JEP, BVM) = 0.357 in 
contrast with JSCDG = 0.184 and JSCJEP = 0.056. Detailed gene lists can be found in 
Table 6.6 and Table 6.7 in Section 6.6. 
 
Classifier transferability (CT) between refined datasets: The CT between refined 
datasets improved. Using HDGG-based classifier built from Harvard tests Michigan, the 
accuracy is 83.7%; meanwhile, using classifier built from Michigan test Harvard, the 
accuracy is 93.8%. Thus, the CT reaches (83.7% + 93.8%)/2 = 88.8%. Recall that before 
BVM, the transferability is only 69.4%. CT significantly improved due to our BVM. 
The above results indicate that using C-loocv, we can effectively minimize the biological 
variability and improve the reliability of datasets. 
 
6.5. CLASSIFICATION IMPROVEMENT 
BVM with C-loocv has many advantages and significances in data mining. Besides 
minimizing the degree of variability in microarray datasets, BVM also increases the 
predicting accuracy during classification process. This was mentioned in Section 6.4.4: 
classifier transferability improved significantly when using classifiers built from refined 
datasets. Therefore, C-loocv can be a very good algorithm to improve the robustness of 
trained classifiers. 
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Many classifiers such as SVM, PCL, HDGG-based classifiers and so on, can predict 
unknown samples with very high accuracy. But in some datasets, some specific samples 
can not be predicted correctly no matter which classification methods/classifiers were 
applied. 
High degree of variability in these datasets is onef the major reasons. In addition, the 
difference of gene expression range between training and testing datasets is another factor. 
By using C-loocv to identify and remove noisy samples from training datasets, the 
situation can be significantly improved. Further, when the baseline is adjusted between 
training and testing datasets, we obtain even better r sults. Next, we will show that our C-
loocv algorithm gives very good results on several public microarray datasets. 
 
A. Prostate cancer microarray dataset: 
Prostate cancer is another very common cancer worldide. One microarray dataset 
focusing on prostate cancer was generated several yars ago (Singh et al, 2002). This 
dataset was created using Affymetrix platform. It includes 12,600 gene probes and 136 
tissue samples. The samples were further divided into two subsets: 102 samples were 
used as training dataset and 34 samples as testing dataset. Both datasets contain tumor 
samples and normal samples. This is a very well design d dataset for testing the 
robustness of classification methods, i.e. building different classifiers from training 
dataset and using each of them to predict the samples in testing dataset. The robustness of 
each classifier can be evaluated by their predicting accuracy. 
Until now, no classification methods can predict the samples in Singh’s testing dataset 
with high accuracy. The highest predicting accuracy is around 50% so far (Tan et al 
 97 
2003b). We also tested our HDGG-based classifier on this dataset. The predicting 
accuracy is nearly 50%. Many reasons may be responsible for the poor predicting 
accuracy. Among them, biological variability is one of the major factors. 
In order to minimize biological variability, we use C-loocv algorithm to refine the 
training dataset and eliminate noisy samples. After BVM, totally 20 samples are 
eliminated. These discarded samples include 15 tumor samples and 5 normal samples. 
When a classifier is built from the refined training dataset and applied to test the original 
testing dataset, the predicting accuracy increases to 73.5%. Though this accuracy rate is 
not very high, it improved greatly compared with the highest previous accuracy rate. 
As discussed in Section 5.3.6, each individual gene’s expression value in two datasets 
should be normalized to identical or similar range before these two datasets can be 
studied together. In Singh’s dataset, nearly one-third of the gene’s expression values in 
training and testing dataset were not in the same range. For example, gene 8’s expression 
range is [-11, 94] across 102 samples in training dataset, but it is [414, 2017] across 34 
samples in testing dataset.  
Per gene range based normalization (Chapter 5) was applied to normalize training and 
testing dataset, the predicting accuracy reaches 85.3%. If C-loocv algorithm is applied on 
the top of gene range based normalization, the predicting accuracy increases to 94.1% 
(only 2 of 34 testing sample were wrongly predicted). (Table 6.5) 
 
B. Breast cancer microarray dataset:  
Breast cancer is the most prevalent cancer in women in the US. One microarray dataset to 
study breast cancer was created by van’t Veer and colleagues (van’t Veer et al 2002). This 
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dataset is also divided into training dataset (78 samples) and testing dataset (19 samples).  
The predicting accuracy was low using current classification methods. When using 
HDGG-based classifier built from training dataset, 6 samples were wrongly predicted. 
After gene range based normalization between training and testing datasets, 5 samples 
were still incorrectly predicted.  
Then, C-loocv algorithm is used to refine the training dataset and eliminate noisy samples. 
Totally 31 samples were eliminated from training dataset. When HDGG-based classifiers 
are built from the refined training dataset on top of gene range based normalization, the 
predicting result improved significantly. Only 2 samples in original testing dataset were 
mis-predicted (Table 6.5). 
 
C. Leukemia dataset:  
In some public cancer related microarray datasets, such as Leukemia dataset (Golub 
1999), the testing samples have been predicted with very high accuracy using current 
classifiers. However, we can get higher predicting accuracy by using baseline adjustment 
and C-loocv algorithm. 
Leukemia dataset includes both training dataset (38 samples) and testing dataset (34 
samples). With our HDGG-based classifier built from the original training dataset, 4 
samples were predicted incorrectly. After baseline adjustment between the training and 
testing dataset and C-loocv, our HDGG-based classifier built from the refined training 
dataset achieved a predicting accuracy of 94.1% (only 2 wrongly predicted samples). 
(Table 6.5) 
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Table 6.5: predicting accuracy improvement with C-loocv and baseline adjustment 
Datasets Original 
Baseline 
adjustment 
C-loocv 
C-loocv with 
Baseline adjustment 
Prostate cancer 50% 85.3% 73.5% 94.1% 
Breast cancer 68.4% 73.7% 68.4% 89.5% 
Leukemia 88.2% 91.2% 91.2% 94.1% 
 
Table 6.5 shows the improvement of prediction accura y using baseline adjustment 
or/and C-loocv. The values in the table are the predicting accuracy rate in percentage. 
HDGG-based classifier was used for predicting testing samples. The second column 
shows the results with the classifier trained from the original training dataset. The 
training dataset was treated with baseline adjustment (3rd column) or C-loocv (4th column) 
respectively before the classifier was built. The fifth column demonstrates the results 
where both treatments were performed. 
 
6.6. CONCLUSION AND DISCUSSION 
High degree of variability in microarray datasets affects data mining results, makes them 
unreliable, and affects the robustness of classifier . Because of the existence of noisy 
samples, the training process may be misled and the established classifiers may not fully 
embody the intrinsic difference between the two classes within one dataset. In other 
words, they are not as robust as they should be since the most significant differences 
between two classes may have been quenched by the noisy samples. Thus, it is hard to 
get high predicting accuracy using such classifiers.  
In microarray data mining, we are the first one to valuate the effect of variability on data 
mining results using comparative methods and to provide methods to minimize 
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variability. Our attempt turned out to be promising and useful. 
We developed the C-loocv algorithm to minimize variability in microarray datasets by 
improving Liu’s algorithm. Compared with Liu’s algorithm, our method is more general. 
HDGG-based classifiers have been proven to be very robust (Chapter 4). LOOCV 
examines the instances one by one and treats every instance equally. Every instance in a 
given training dataset participates to decide the testing instance’s class type. This is better 
than the k-NN method, in which only k instances are us d to predict the testing instance. 
The choice of value ‘k’ is important because different k value may cause different 
predicting result, and it is a difficult issue. 
The C-loocv algorithm effectively eliminates noisy samples and reduces variability. After 
datasets are refined by C-loovc, the predicting accuracy increases significantly, and the 
consistency of data mining results is also improved.  
However, though the consistency of data mining results is improved by BVM, it did not 
reach our expected level. For example, there is still big divergence of data mining results 
between Harvard and Michigan datasets as shown in Table 6.3, Table 6.6 and Table 6.7. 
We also tested another dataset (Singh et al, 2002) and obtained similar results. We mined 
top 20 genes from original training and testing datase s in this prostate dataset, and only 2 
genes were shared in the two top 20 gene sets. After BVM with C-loocv, we got 6 
common genes in both sets (recall that the predicting accuracy has been dramatically 
improved after C-loocv). This large gene difference (14 genes were difference between 
two sets) indicated that the training dataset and testing dataset are not very consistent 
with each other, even though biological variability has been minimized. 
The fact that the ultimate results did not reach 100% consistency might have been caused 
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by many reasons.  One of them is the tradeoff of bilog cal variability versus bias. Most 
microarray datasets have large number of genes and relatively small number of samples. 
These samples may not fully reflect the intrinsic class features, and they may lead to data 
mining results which are not fully consistent. 
During biological variability minimization, if a small value of threshold τ is chosen, 
fewer samples are eliminated and the data mining results may not improve significantly. 
On the other hand, if larger value of τ is chosen, more samples are removed and few 
samples remain, the bias may rise and mislead the results. 
Based on our results in this chapter, we realize that the variability and some other reasons 
make big impact on the HDGGs we mined. In order to get more reliable HDGGs from 
current highly variable microarray datasets, we are going to mine so called “invariant 
patterns” from several microarray datasets which focus on a common disease. The 
methods and results will be shown in Chapter 7. 
6.7. APPENDIX 
In this section we will show the sets of discriminat g genes and the sets of HDGGs 
mined from Michigan and Harvard lung cancer datasets. 
6.7.1 The sets of discriminating genes (DGs) 
Discriminating genes have been proved to be of great importance, because they contain 
valuable information in each specific dataset. The similarity between the sets of 
discriminating genes from two datasets is another good criterion to test biological 
variability. If there is high degree of biological variability in datasets, the discriminating 
genes and the number of discriminating genes from these datasets will become quite 
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different. Table 6.6 shows the DG sets from two lung cancer datasets before and after 
biological variability minimization (BVM). 
Table 6.6: Discriminating genes in Harvard and Michigan lung cancer datasets 
Original datasets Refined datasets 
Michigan Harvard Michigan Harvard 
640 223 123 123 
845 483 640 640 
1210 640 845 796 
1344 845 1344 845 
2302 997 1814 961 
2555 1086 1981 1035 
2607 1344 2040 1100 
2688 1526 2275 1344 
2910 1690 2287 1600 
2956 1814 2555 1797 
3104 2040 2607 1814 
3207 2275 2688 1981 
3550 2287 2910 2040 
4351 2508 3136 2287 
4657 2607 3581 2555 
 2688 3895 2607 
 2736 3945 2688 
 2910 4020 2910 
 2956 4145 2941 
 3136 4165 2956 
 3581  3012 
 3784  3038 
 3895  3284 
 3945  3581 
 4020  3895 
 4145  4020 
 4180  4165 
 4366  4351 
 4598  4657 
 
The contents in Table 6.6 are the discriminating gene index numbers. We use the bold 
font to show discriminating genes shared by both Harvard and Michigan datasets. Before 
BVM, there are 16 and 29 discriminating genes in Michigan and Harvard datasets 
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respectively. Among them only 7 common DGs are in both sets (JSCDG = 18.4%). After 
refining the datasets by BVM, the numbers of discriminating genes in two datasets 
become 20 and 29 respectively, and 14 of them are shared by two datasets (JSC(DG, BVM) = 
40%). The improvement of common DGs indicates that C-loocv algorithm can 
effectively reduce biological variability. 
6.7.2. The sets of HDGGs (JEPs) 
HDGGs have been proved to be very useful for discovering the inherent distinctions 
between different classes within one dataset (Chapter 4). It is also one important 
characteristic of a given dataset. The similarity of the sets of HDGGs from two datasets is 
also a good criterion to test biological variability. Table 6.7 lists the top 10 signature JEPs 
in diseased class in Michigan and Harvard datasets. The details about the sets of HDGGs 
in these two datasets will be described in Chapter 7. 
Note: In order to show more information, we leave ‘+’ and ‘-’ sign in the table, so the 
patterns in the table are actually JEPs. When the signs are removed, each JEP will 
become one HDGG. There are only 9 JEPs in original/refined Harvard dataset. 
Table 6.7: HDGGs (JEPs) in Harvard and Michigan lung cancer datasets 
Original datasets Refined datasets 
Michigan Harvard Michigan Harvard 
{2910- } {2910- } {711-} {640-} 
{845- } {3550- 4351- } {845-} {845-} 
{1344- } {3550- 3207- } {1344-} {1344-} 
{1814- } {2607- 3550- } {1814-} {2607-} 
{2040- } {2607- 2302- } {2040-} {2287-} 
{3895- } {2607- 1210+ } {2275-} {2688-} 
{3136+ 483- } {3550- 4351- } {2287-} {2910-} 
{3136+ 483- } {4351- 2302- } {2607-} {2956-} 
{3136+ 5126- } {4351- 1210+ } {2910-} {4351-} 
{3136+ 65- }  {3136+}  
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Comparing the HDGGs mined from two lung cancer datasets, we find that only one 
HDGG is shared by two original datasets (first & second columns) whereas five HDGGs 
are shared by two C-loocv refined datasets (third & fourth columns). 
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Chapter 7: DISCOVERY OF INVARIANT PATTERNS 
7.1. MOTIVATION AND OUR APPROACH 
During our microarray dataset study, we observed that the current microarray datasets we 
focused on have very high variability. The existence of variability affects the quality and 
transferability of mined patterns. In our study, among the mined HDGGs from one 
dataset, it is difficult to tell which HDGGs are intri sic patterns and which ones are 
artifacts caused by variability. Most importantly, some intrinsic patterns may have been 
covered up by the variability and can not be mined from such highly variable datasets. 
Even though biological variability has been minimized by our C-loocv algorithm, other 
factors also exist in microarray datasets that influence the mined patterns. 
In order to better understand the mechanism underlying diseases, we will mine “invariant 
patterns” from different datasets concerning a commn disease. We define invariant 
pattern (IVP) as following: if a pattern is a signature HDGG in one dataset and it has very 
high support in all other datasets (even though it might not be a jumping emerging 
pattern), we call this pattern an invariant pattern. In contrast, other HDGGs are defined 
as variant patterns (VP).  
In this chapter, (1) we mine both invariant patterns and variant patterns from multiple 
microarray datasets concerning a common disease; (2) we prove that invariant patterns 
are more related with the disease of interest than variant patterns; (3) we demonstrate 
again that C-loocv is an effective algorithm for minimizing variability in datasets, and for 
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helping us to mine more invariant patterns. 
We hope that invariant patterns can help shed light on the mechanism of the given 
disease underlying the given datasets based on the following rationale. If one pattern is 
involved in the disease-specific gene interaction networks and pathways, this pattern is 
very likely to be a HDGG, or to have very high "verification" frequency in any 
microarray datasets concerning this disease. On the other hand, if a pattern has very high 
frequency in one dataset, but has very low frequency i  other datasets concerning the 
same disease, it is more reasonable to deduce that this pattern might be an artifact caused 
by noise or technical differences. 
 
7.2. MATERIALS AND METHODS 
We use the same lung cancer microarray datasets (namely Michigan and Harvard) as 
used in Chapter 6. The details about them were describ d in Chapter 6. After treating the 
datasets by C-loocv algorithm, we obtain two more datasets: Refined Michigan (RM) and 
Refined Harvard (RH). For our convenience, the two datasets not treated with C-loocv 
are called Original Michigan (OM) and Original Harvd (OH) respectively. Thus, totally 
four datasets are studied in this chapter (OM, RM, OH and RH). 
The method we use to mine invariant patterns from any two given microarray datasets is 
the following: a) in each given microarray dataset, every gene’s expression value is 
discretized as 0 or 1 using the entropy based method; b) the iterative gene club formation 
algorithm and border differential algorithm are applied to mine HDGGs from each of the 
dataset; c) the HDGGs mined from the diseased classin each dataset are collected; d) the 
frequency of each HDGG is determined in both datasets; e) the invariant patterns are 
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determined based on the HDGGs’ frequency in each dataset.  
In this chapter, the above method will be applied to mine HDGGs and IVPs from dataset 
pairs: one dataset from Michigan (original or refind) and the other one from Harvard 
(original or refined). Specifically, we will mine HDGGs and IVPs from four pairs of 
datasets (OM vs OH; RM vs OH; OM vs RH; RM vs RH) respectively. The data mining 
results from dataset pairs (OM vs OH and RM vs RH) are of our great interest and will be 
studied thoroughly. The results from dataset pairs RM vs OH and OM vs RH will be used 
as reference. 
After finding the invariant patterns and variant paterns, the known biological functions 
of the discriminating genes within those patterns are investigated and evaluated. The 
number and percentage of invariant patterns within mi ed HDGGs from different dataset 
pairs are also compared and discussed. 
 
7.3. RESULTS ON INVARIANT HDGG PATTERNS 
Table 7.1 lists the HDGGs mined from OM and OH datase s. The columns from left to 
right are: HDGG’s index, emerging patterns which include the involved discriminating 
genes in the HDGG, frequency of the HDGG in the OM dataset, frequency of the HDGG 
in the OH, and whether the HDGG is considered as an invariant pattern, respectively. We 
use the frequency of 95% as threshold to determine wh ther a HDGG is an IVP, i.e. if 
one HDGG’s frequency in both datasets is higher than 95%, we consider it as an IVP. 
Otherwise, it is a VP. 
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Table 7.1: IVPs and VPs from OM and OH datasets 
Index Emerging patterns 
Frequency in 
OM (%) 
Frequency in 
OH (%) IVP 
1 {845 -} 100.0% 98.4% Y 
2 {1344 -} 100.0% 97.8% Y 
3 {1814 -} 100.0% 96.8% Y 
4 {2040 -} 100.0% 88.7%  
5 {2910 -} 100.0% 99.5% Y 
6 {3895 -} 100.0% 97.3% Y 
7 {3136 +, 483 -} 100.0% 13.4%  
8 {3136 +, 4126 -} 100.0% 5.4%  
9 {3136 +, 65 -} 100.0% 9.7%  
10 {3136 +, 115 -} 100.0% 1.1%  
11 {3136 +, 725 -} 100.0% 13.4%  
12 {3136 +, 4228 +} 100.0% 13.4%  
13 {3136 +, 3829 +} 100.0% 15.1%  
14 {3136 +, 3925 +} 100.0% 12.4%  
15 {3136 +, 1214 +} 100.0% 8.1%  
16 {3136 +, 1722 +} 100.0% 8.1%  
17 {3136 +, 2126 +} 100.0% 14.5%  
18 {3136 +, 4757 +} 100.0% 12.9%  
19 {483 -, 4228 +, 5126 -} 100.0% 27.4%  
20 {483 -, 4228 +, 115 -} 100.0% 12.4%  
21 {640 -} 97.7% 98.4% Y 
22 {2688 -} 98.8% 98.4% Y 
23 {2607 -, 3550 -} 97.7% 99.5% Y 
24 {2607 -, 2302 -} 74.4% 99.5%  
25 {2607 -, 1210 +} 8.1% 99.5%  
26 {4351 - , 3550 -} 90.7% 99.5%  
27 {4351 - , 2302 -} 67.4% 99.5%  
28 {4351 - , 1210 +} 8.1% 99.5%  
29 {2607 -, 2302 -} 74.4% 99.5%  
30 {2607 -, 1210 +} 8.1% 99.5%  
31 {2302 -, 4351 –} 67.4% 99.5%  
 
Among the 31 HDGGs mined from the two original datasets, 8 of them are IVPs because 
their frequencies are higher than 95% in both datasets, and the other 23 HDGGs are VPs 
which exhibit high frequency in only one dataset.  
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Table 7.2 lists the IVPs and VPs mined from RM and RH datasets. A total of 26 HDGGs 
are mined from these two datasets and 14 of them ar IVPs.  
Table 7.2: IVPs and VPs from RM and RH datasets 
Index Emerging patterns 
Frequency 
in RM (%) 
Frequency 
in RH (%) 
IVP 
1 {640 -} 100.0% 100.0% Y 
2 {845 -} 100.0% 100.0% Y 
3 {1344 -} 100.0% 100.0% Y 
4 {1814 -} 100.0% 99.4% Y 
5 {2040 -} 100.0% 99.4% Y 
6 {2275 -} 100.0% 40.3%  
7 {2287 -} 100.0% 100.0% Y 
8 {2607 -} 100.0% 100.0% Y 
9 {2910 -} 100.0% 100.0% Y 
10 {3136 +} 100.0% 2.3%  
11 {3581 -} 100.0% 98.9% Y 
12 {3895 -} 100.0% 98.9% Y 
13 {4020 -} 100.0% 99.4% Y 
14 {2688 -} 98.8% 100.0% Y 
15 {2956 -} 97.6% 100.0% Y 
16 {4351 -} 100.0% 100.0% Y 
17 {3284 -, 4657 -} 91.9% 100.0%  
18 {3284 -, 796 +} 90.7% 100.0%  
19 {3284 -, 2941 +} 69.9% 100.0%  
20 {3284 -, 1600 +} 20.5% 100.0%  
21 {3284 -, 3038 +} 45.8% 100.0%  
22 {3284 -, 961 +} 30.1% 100.0%  
23 {3284 -, 1035 +} 66.3% 100.0%  
24 {3284 -, 1100 +} 13.3% 100.0%  
25 {3284 -, 1797 +} 21.7% 100.0%  
26 {3284 -, 3012 +} 69.9% 100.0%  
 
From these two Tables, we notice that biological variability has big impact on the mined 
HDGGs. Some HDGGs have very high frequency in one dataset, but have quite low 
frequency in the other dataset. For example, in Table 7.1, patterns {3136+, 115-}, {3136+, 
65- } have 100% frequencies in OM dataset; but their fr quencies are less than 10% in 
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OH dataset. Patterns {4351- , 1210+}, {2607-, 1210+} have nearly 100% frequencies in 
OH dataset, but have lower than 10% frequencies in OM. These results demonstrate that 
biological variability greatly affects data mining result and reduce the quality of mined 
HDGGs. Therefore, further study is needed to sort out real valuable HDGGs, which are 
IVPs as our concern, for the understanding of diseases. 
In the following sections, first we prove that IVPs are more related with cancer diseases 
than VPs; then we demonstrate again that the C-loocv algorithm can effectively improve 
the invariance of datasets. 
7.3.1. Biological function comparison of the discriminating genes 
within IVPs versus VPs 
As shown in Table 7.2, 14 IVPs and 12 VPs are identfi d from two refined lung cancer 
datasets (RM vs RH). In order to evaluate the quality of these patterns, one good and 
direct way is to investigate the biological functions of each discriminating gene (DG) in 
these patterns since the set of DGs (total 14 DGs)  in IVPs are completely different from 
that in VPs (total 13 DGs). Each discriminating gene’s function will be described in 
Section 7.4.2.  
Note: If there were overlapping of DGs in IVPs with t ose in VPs, we should have 
further investigated the relationship between these DGs’ involved in one given HDGG. 
According to the gene’s functions by biological studies, we find that among the 14 DGs 
within IVPs, 7 DGs have been shown to be related with tumors. The ratio is 7/14 = 
50.0%. In contrast, among the 13 DGs within VPs, only 3 genes have been proven to be 
related with tumors, and the ratio is 3/13 = 23.1%.  
In our cancer study, theoretically, if no variability exists in microarray datasets, all DGs 
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in both IVPs and VPs should be related with tumors. Therefore, the above results indicate 
that, using datasets with high variability, IVPs are more robust than VPs to understand 
diseases. They may provide useful clues for finding some unknown gene’s functions and 
for discovering the potential gene interactions in tumor occurrence. 
We also investigated the functions of the discriminating genes listed in Table 7.1, which 
were mined from the original datasets (OM vs OH). We randomly chose several 
discriminating genes for function analysis and got similar results. 
7.3.2. C-loocv effectively improves the quality of mined HDGGs 
We compare the IVPs and VPs mined from different dataset pair combinations. These 
HDGGs are listed in Table 7.1, 7.2, 7.4 and 7.5. 
(1) The numbers of IVPs mined from the refined datase  pairs are larger than that from 
the original ones. Meanwhile, the percentage of IVPs in HDGGs also increases (Table 
7.3). Table 7.3 lists the number and the percentage of IVPs in HDGGs mined from 4 
different dataset pairs. 
Table 7.3: The number and percentage of IVPs mined from four dataset pairs 
Index Datasets No. of IVPs No. of HDGGs % of IVPs 
1 OM vs OH 8 31 25.8% 
2 OM vs RH 11 36 30.6% 
3 RM vs OH 11 22 50.0% 
4 RM vs RH 14 26 53.8% 
 
(2) Comparing the set of IVPs from different datase pair, we notice that one IVP {2607, 
3550} is mined from the original datasets; in contras , a different IVP {2607} is mined 
from the refined datasets, which is the subset of the former pattern. This means that one 
discriminating gene 2607 may be enough to determine the disease. The occurrence of 
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gene 3550 in pattern {2607, 3550} may be an artifact. 
(3) Some IVPs fail to be mined from the original datasets, but they can be mined from the 
refined datasets. By comparing the sets of IVPs mined from different dataset pairs in 
Table 7.3, we find the relationship among the IVP sets: A ⊂ B ⊂  D, and A ⊂ C ⊂  D 
(Figure 7.1). Here, A is the set of IVPs mined from dataset pair OM vs OH; B is IVP set 
from OM vs RH; C is the IVP set from RM vs OH, and D is the IVP set from RM vs RH 
dataset pair. Note: We consider the IVP {2607, 3550} and IVP {2607} as the same 
pattern. 
 
Figure 7.1: Relationship of the sets of IVPs from different da aset pairs 
Several IVPs such as {2040}, {2956}, {4351}, which failed to be mined from the 
original datasets, have very high frequency in both refined datasets. The discriminating 
genes in these IVPs are proven to be related to tumrs. 
From the above results, we conclude that: (A) C-loocv effectively minimizes the 
variability of microarray datasets; (B) C-loocv improves the overall quality of the 
HDGGs with respect to IVPs mined from the refined datasets. 
7.3.3. Discussion 
In order to better understand diseases, we identifid invariant patterns from multiple 
datasets concerning a common disease. In this chapter, we obtained both invariant 
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patterns and variant patterns from the datasets concerni g lung cancer. Compared with 
variant patterns, there is a higher proportion of discriminating genes in invariant patterns 
which are known to be related to tumors. This suggests that invariant patterns are more 
valuable for revealing the mechanism of specific diseases. 
Our C-loocv algorithm, which was developed to minimize the biological variability of 
datasets, can effectively help us to mine high-quality IVPs from microarray datasets. 
Indeed, the quality of HDGGs mined from the C-loocv refined datasets is higher than that 
from the original datasets. 
95% of frequency was used as threshold to determine invariant patterns in this study. We 
also tried 90% and 85% of frequency as thresholds and got similar results: (A) the 
invariant patterns were more related with tumors than variant patterns; (B) the number 
and the proportion of invariant patterns in mined HDGGs were higher from the refined 
datasets than that from original datasets. 
With the development of modern molecular biology, more and more genes have been 
identified and sequenced. However, the specific functio s of many genes are still 
unknown or still under investigation. Functional genomics is a relatively new field of 
molecular biology that attempts to use numerous known gene-sequence data to determine 
unknown gene functions and interactions. It usually t kes a long time to understand one 
specific gene’s function. We hope that our data mining results can provide valuable clues 
for gene function study. 
According to our results, the genes in invariant pat erns tend to be potentially important 
for the occurrence of lung cancer. So far, more than 40% of the discriminating genes 
within these IVPs have not been found to be functioally related with tumors. We 
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recommend further study by biomedical scientists to determine the exact functions of 
these genes. 
7.4. APPENDIX  
7.4.1. IVPs and VPs in OM vs RH and in RM vs OH datasets 
Table 7.4 lists the IVPs and VPs mined from dataset OM vs RH. A total of 36 HDGGs 
are mined from these two datasets and 11 of them ar IVPs.  
Table 7.4: IVPs and VPs from OM and RH dataset pair 
Index Emerging patterns 
Frequency in 
OM (%) 
Frequency in 
RH (%) 
IVP 
1 {845 -} 100.0% 100.0% Y 
2 {1344 -} 100.0% 100.0% Y 
3 {1814 -} 100.0% 99.4% Y 
4 {2040 -} 100.0% 99.4% Y 
5 {2910 -} 100.0% 100.0% Y 
6 {3895 -} 100.0% 98.9% Y 
7 {3136 +, 483 -} 100.0% 2.3%  
8 {3136 +, 5126 -} 100.0% 0.0%  
9 {3136 +, 65 -} 100.0% 1.1%  
10 {3136 +, 115 -} 100.0% 2.3%  
11 {3136 +, 725 -} 100.0% 2.3%  
12 {3136 +, 4228 +} 100.0% 2.3%  
13 {3136 +, 3829 +} 100.0% 2.3%  
14 {3136 +, 3935 +} 100.0% 2.3%  
15 {3136 +, 1214 +} 100.0% 0.0%  
16 {3136 +, 1722 +} 100.0% 1.1%  
17 {3136 +, 2126 +} 100.0% 2.3%  
18 {3136 +, 4757 +} 100.0% 2.3%  
19 {483 -, 4228 +, 5126 -} 100.0% 9.7%  
20 {483 -, 4228 +, 115 -} 100.0% 73.9%  
21 {640 -} 97.7% 100.0% Y 
22 {2287 -} 96.5% 100.0% Y 
23 {2607 -} 98.8% 100.0% Y 
24 {2688 -} 98.8% 100.0% Y 
25 {2956 -} 96.5% 100.0% Y 
26 {4351 -} 91.9% 100.0%  
27 {3284 -, 4657 -} 91.9% 100.0%  
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28 {3284 -, 796 +} 90.7% 100.0%  
29 {3284 -, 2941 +} 70.9% 100.0%  
30 {3284 -, 1600+} 20.9% 100.0%  
31 {3284 -, 3038 +} 48.8% 100.0%  
32 {3284 -, 961 +} 66.3% 100.0%  
33 {3284 -, 1035 +} 23.3% 100.0%  
34 {3284 -, 1100 +} 34.9% 100.0%  
35 {3284 -, 1797 +} 22.1% 100.0%  
36 {3284 -, 3012 +} 72.1% 100.0%  
 
 
Table 7.5 lists the IVPs and VPs mined from OH vs RM datasets. A total of 22 HDGGs 
are mined from these two datasets and 11 of them ar IVPs. 
Table 7.5: IVPs and VPs from RM and OH datasets 
Index Emerging patterns 
Frequency in 
RM (%) 
Frequency in 
OH (%) 
IVP 
1 {845 -} 100.0% 98.4% Y 
2 {1344 -} 100.0% 97.8% Y 
3 {1814 -} 100.0% 96.8% Y 
4 {2040 -} 100.0% 88.7%  
5 {2275 -} 100.0% 58.1%  
6 {2287 -} 100.0% 96.2% Y 
7 {3136 +} 100.0% 15.6%  
8 {3581 -} 100.0% 80.1%  
9 {3895 - } 100.0% 97.3% Y 
10 {4020 -} 100.0% 95.2% Y 
11 {2910 -} 100.0% 99.5% Y 
12 {640 -} 100.0% 98.4% Y 
13 {2688 -} 98.8% 98.4% Y 
14 {2607 -, 3550 -} 100.0% 99.5% Y 
15 {2607 -, 2302 -} 68.7% 99.5%  
16 {2607 -, 1210 +} 8.4% 99.5%  
17 {4351 -, 3550 -} 100.0% 99.5% Y 
18 {4351 -, 2302 -} 68.7% 99.5%  
19 {4351 -, 1210 +} 8.4% 99.5%  
20 {2607 -, 2302 -} 68.7% 99.5%  
21 {2607 -, 1210 +} 8.4% 99.5%  
22 {2302 -, 4351 -} 68.7% 99.5%  
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7.4.2. Biological functions of the related genes 
Table 7.6 lists the genes that are involved in the IVPs and HDGGs mined from both the 
original datasets and the refined datasets. In this section, we introduce the genes listed in 
Table 7.2 and the known functions of these genes. Meanwhile, we also randomly choose 
several genes from Table7.6 and discuss their functions. 
Table 7.6: Description of DGs involved in HDGGs in Tables 7.1and 7.2 
Index 
number 
Gene 
number 
Uni gene 
name Description 
1 65 GTF2B general transcription factor IIB 
2 115 RPS6KA1 
ribosomal protein S6 kinase, 90kDa, polypeptide 
1 
3 483 POLR2C 
polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 
4 640 PTPRH protein tyrosine phosphatase, receptor type, H 
5 725 KDR 
kinase insert domain receptor (a type III receptor 
tyrosine kinase) 
6 796 CTNNA2 catenin (cadherin-associated protein), alpha 2 
7 845 FRAP1 
FK506 binding protein 12-rapamycin associated 
protein 1 
8 961 RPL18 ribosomal protein L18 
9 1035 ANXA3 annexin A3 
10 1100 DRP2 dystrophin related protein 2 
11 1210 VAMP2 
vesicle-associated membrane protein 2 
(synaptobrevin 2) 
12 1214 ZNF345 zinc finger protein 345 
13 1344 PPP3CC 
protein phosphatase 3 (formerly 2B), catalytic 
subunit, gamma isoform (calcineurin A gamma) 
14 1600 FXN Frataxin 
15 1722 MAGEA2 melanoma antigen family A, 2 
16 1797 DDT D-dopachrome tautomerase 
17 1814 PTPRU protein tyrosine phosphatase, receptor type, U 
18 2040 SLC2A5 
solute carrier family 2 (facilitated 
glucose/fructose transporter), member 5 
19 2126 MAGEA5 melanoma antigen family A, 5 
20 2275 3.8-1 MHC class I mRNA fragment 3.8-1 
21 2287 SGCD 
sarcoglycan, delta (35kDa dystrophin-associated 
glycoprotein) 
22 2302 OPRK1 opioid receptor, kappa 1 
23 2607 ZNF268 zinc finger protein 268 
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24 2688 NCOA1 nuclear receptor coactivator 1 
25 2910 RNF113A ring finger protein 113A 
26 2941 MDH1 malate dehydrogenase 1, NAD (soluble) 
27 2956 HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 
28 3012 CAMP cathelicidin antimicrobial peptide 
29 3038 NEUROD1 neurogenic differentiation 1 
30 3136 ERP29 endoplasmic reticulum protein 29 
31 3284 CYP11A1 
cytochrome P450, family 11, subfamily A, 
polypeptide 1 
32 3550 BLMH bleomycin hydrolase 
33 3581 GLB1 galactosidase, beta 1 
34 3829 PENK Proenkephalin 
35 3895 FASN fatty acid synthase 
36 3925 TARS threonyl-tRNA synthetase 
37 4020 ATP6V0D1 
ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d1 
38 4126 AGC1 
aggrecan 1 (chondroitin sulfate proteoglycan 1, 
large aggregating proteoglycan, antigen 
identified by monoclonal antibody A0122) 
39 4228 CD3G CD3g molecule, gamma (CD3-TCR complex) 
40 4351 PRM1 protamine 1 
41 4657 CCT5 chaperonin containing TCP1, subunit 5 (epsilon) 
42 4757 KCNB1 
potassium voltage-gated channel, Shab-related 
subfamily, member 1 
43 5126 HTATIP HIV-1 Tat interacting protein, 60kDa 
 
Gene 65 (general transcription factor IIB): general transcription factor IIB is a ubiquitous 
factor required for transcription initiation by RNA polymerase II. It was suggested that 
TFIIB serves as a bridge between the "TATA"-binding factor (TFIID) and RNA 
polymerase II during pre-initiation complex assembly. Recently, it was also found that 
GTFIIB can be a target of acidic activators.  
Gene 483 (polymerase (RNA) II (DNA directed) polypeptide C, 33kDa): This gene 
encodes the third largest subunit of RNA polymerase II, the polymerase responsible for 
synthesizing messenger RNA in eukaryotes. The product of this gene contains a cysteine 
rich region and exists as a heterodimer with another polymerase subunit, POLR2J. These 
two subunits form a core subassembly unit of the polymerase. The expression of this 
 118 
gene is regulated during muscle differentiation (Corbi et al 2005). 
Gene 640 (PTPRH) and gene 1814 (PTPRU): The proteins encoded by these two genes 
are a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be 
signaling molecules that regulate a variety of cellular processes including cell growth, 
differentiation, mitotic cycle, and oncogenic transformation. The genes were shown to be 
expressed primarily in brain and liver, and at a lower level in heart and stomach. It was 
also found that these two genes expressed in several cancer cell lines, but not in the 
corresponding normal tissues (Trapasso et al 2004).  
Gene 796 (catenin (cadherin-associated protein), alpha 2): The protein encodes by this 
gene is a subunit of alpha N-catenin, a linker betwe n cadherin adhesion receptors and 
the actin cytoskeleton. It is essential for stabilizing dendritic spines in rodent 
hippocampal neurons in culture. It has been proven that alpha N-catenin is a key 
regulator for the stability of synaptic contacts (Abe et al 2004). 
Gene 845 (FK506 binding protein 12-rapamycin associated protein 1 or Frap1): The 
protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related 
kinases. The known function for this protein is kinase activity and binding. It has been 
reported that Frap is a candidate gene for the plasmacytoma resistance locus Pctr2 and 
can act as a tumor suppressor gene (Bliskovsky et al 2003). 
Gene 961 (ribosomal protein L18): This gene encodes the large subunit of ribosomal 
protein. This is one of the proteins that binds andprobably mediates the attachment of the 
5S RNA into the large ribosomal subunit, where it forms part of the central protuberance. 
Gene 1035 (annexin A3): ANXA3 is present in healthy epithelial cells, and is relatively 
less abundant in individual tumor cells of increasing Gleason pattern (GP), despite 
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exhibiting higher overall tissue abundance in tumors. ANXA3 staining was 
predominantly cytoplasmic. Strongly staining single c lls, possibly phagocytes, were 
interspersed in highly dedifferentiated GP5 tumor areas among tumor cells without 
measurable ANXA3. (Wozny et al 2007). 
Gene 1100 (dystrophin related protein 2): DRP protein is them mbers of the dystrophin 
family, which performs a critical role in the mainte ance of membrane-associated 
complexes at points of intercellular contact in verteb ate cells. Dystrophin related protein 
2 is predicted to resemble certain short C-terminal isoforms of dystrophin and dystrophin-
related protein 1 (DRP1 or utrophin). DRP2 is expressed principally in the brain and 
spinal cord. 
Gene 1210(vesicle-associated membrane protein 2 (synaptobrevin 2)): Vesicle-associated 
membrane protein (VAMP) (or synaptobrevin), a type II membrane protein of small 
synaptic vesicles, is essential for neuroexocytosis because its proteolysis by tetanus and 
botulinum neurotoxins types B, D, F and G blocks neurotransmitter release. It implies the 
existence of a synaptophysin-VAMP-2 complex is helpful for the processes of vesicle 
docking and fusion with the presynaptic membrane (Washbourne et al 1995). 
Gene 1344 (protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform 
(calcineurin A gamma)): The putative function of this gene includes: Calcium-dependent, 
calmodulin-stimulated protein phosphatase. This subunit may have a role in the 
calmodulin activation of calcineurin. 
Gene 1600 (frataxin): Frataxin is a small protein, localized to the mitochondrion. The 
function of frataxin is not entirely clear, but it seems to be involved in assembly of 
irosulfur clusters. Deficiency of frataxin is the cause of Friedrich’s ataxia, a hereditary 
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trinucleotide repeat disorder. 
Gene 1797 (D-dopachrome tautomerase): This gene’s expression i  tightly related with 
Macrophage migration inhibitory factor (MIF) activiy. When UVB light was used to 
induce an experimental inflammation in normal human skin, the D-dopachrome 
tautomerase’s expression increases significantly accomplishing with skin’s inflammation 
(Sonesson et al 2003).  
Gene 2040 (solute carrier family 2 (facilitated glucose/fructose transporter), member 5): 
Another name of this gene is GLUT5, which is expressed on the brush border membrane 
of human small intestinal enterocytes (Davidson et al 1992). GLUT5 is a fructose 
transporter and may be largely responsible for the uptake of fructose from the lumen of 
the small intestine (Burant et al 1992). Godoy and colleagues (Godoy et al 2006) used 
situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 over- 
expression in breast cancer. The extensive expression of GLUT2 and 5 (glucose/fructose 
and fructose transporters, respectively) in malignant human tissues indicates that fructose 
may be a good energy substrate in tumor cells. 
Gene 2275 (MHC class I mRNA fragment 3.8-1): specific function is under investigation. 
Gene 2287 (sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)): The protein 
encoded by this gene is one of the four known components of the sarcoglycan complex, 
which is a subcomplex of the dystrophin-glycoprotein complex (DGC). DGC forms a 
link between the F-actin cytoskeleton and the extracellular matrix. This protein is 
expressed most abundantly in skeletal and cardiac muscle. The mutations in this gene 
have been associated with autosomal recessive limb-g rdle muscular dystrophy and 
dilated cardiomyopathy. Alternatively spliced transcript variants encoding distinct 
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isoforms have been observed. 
Gene 2607 (zinc finger protein 268): ZNF268 plays a role in the development of human 
fetal liver and the differentiation of blood cells. There are many splicing isoforms of ZNF 
268 genes. ZNF268c mRNA was detected only in tumor cells. ZNF268a, ZNF268b1 and 
ZNF268b2, were also detected in tumor cell lines (Shao et al 2006). 
Gene 2688 (nuclear receptor coactivator 1): The nuclear receptor coactivator 1(NCOA1) 
is a transcriptional co-reluatory protein which is recruited to DNA promotion sites by 
ligand activated nuclear receptors. NCOA1 accumulates histone which makes 
downstream DNA more accessible to transcription. NCOA1 is also frequently called 
steroid receptor coactivator-1(SRC-1). It has been r ported that enhanced androgen 
receptor activity through elevated expression of SRC-1 in the development of more 
aggressive disease in men with prostate cancer (Agoulnik et al 2005). 
Gene 2910 (RNF 113A): RNF 113A is also called RNF113 or ZNF183 which encodes a 
ring finger protein 113A. It is a novel gene whose function cannot directly be inferred 
from its sequence analysis. RNF113A is a ubiquitously expressed protein that contains a 
RING type zinc finger and a C3H1 type zinc finger. 
Gene 2941 (malate dehydrogenase 1, NAD (soluble)): Malate dehy rogenase catalyzes 
the reversible oxidation of malate to oxaloacetate, utilizing the NAD/NADH cofactor 
system in the citric acid cycle. The protein encoded by this gene is localized to the 
cytoplasm and may play pivotal roles in the malate-aspartate shuttle that operates in the 
metabolic coordination between cytosol and mitochondria. 
Gene 2956 (hydroxysteroid (17-beta) dehydrogenase 4): The peroxisomal 17β-
hydroxysteroid dehydrogenase type 4 (17β-HSD 4, gene name HSD17B4) catalyzes the 
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oxidation of estradiol with high preference over the reduction of estrone. The expression 
of 17β-HSD 4 has been detected in several human cancer cell lines (Launoit et al 1999). 
Gene 3012 (cathelicidin antimicrobial peptide): The cathelicid n antimicrobial peptide 
(CAMP) is an important innate defense peptide. It showed the expression of CAMP in 
nasal mucosa supporting its role in innate defenses against inhaled pathogens (Ooi et al 
2007). 
Gene 3038 (neurogenic differentiation 1): This gene encodes a member of the NeuroD 
family of basic helix-loop-helix (bHLH) transcription factors. The protein forms 
heterodimers with other bHLH proteins and activates transcription of genes that contain a 
specific DNA sequence known as the E-box. It regulates expression of the insulin gene, 
and mutations in this gene result in type II diabetes mellitus.  
Gene 3136(ERp29): ERp29 is a recently discovered ER resident that has been implicated 
in secretory protein synthesis and appears to be of similar prevalence to the established 
major reticuloplasmins (Hubbard et al. 2000). The novel protein sequence of ERp29 
exhibits characteristic features of a reticuloplasmin (signal peptide, ER retention motif), 
and localization to the ER lumen was comprehensively supported at the biochemical level 
(Demmer et al. 1997). Hubbard found that cancer cells have more ERp29 than normal 
cells, and suggested that if it does help make key cellular components, perhaps it could be 
targeted at preventing cancer growth (Shnyder S., Hubbard M., 2002). 
Gene 3284 (cytochrome P450, family 11, subfamily A, polypeptide 1): This gene 
encodes a member of the cytochrome P450 superfamily of enzymes. The encoded 
enzyme catalyzes many reactions involved in drug metabolism and synthesis of 
cholesterol, steroids and other lipids which includes the biosynthesis of sex-steroid 
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hormones. Recently, the relationship between common variation in CYP11A and breast 
cancer risk among African-Americans, Latinas, Japanese-Americans, native Hawaiians 
have been reported (Setiawan et al 2006). 
Gene 3550 (bleomycin hydrolase): The normal physiological role f BLM hydrolase is 
unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by 
hydrolyzing the carboxamide bond of its B-aminoalanin mide moiety thus protecting 
normal and malignant cells from BLM toxicity. 
Gene 3581 (galactosidase, beta 1): galactosidase, beta 1 encod s a protein called beta-
galactosidase. A deficiency of (GLB1) causes G(M1)-gangliosidosis which is a 
lysosomal storage disorder (Caciotti et al 2005).The GLB1 gene gives rise to the GLB1 
lysosomal enzyme and to the elastin binding protein (EBP), involved in elastic fiber 
deposition. 
Gene 3895 (Fatty acid synthase): Fatty acid synthase (FAS) is a multienzyme protein 
required for the conversion of acetyl coenzyme A and malonyl coenzyme A to palpitate. 
High levels of FAS expression have been found in may human cancers, including breast, 
prostate and colon (Notarnicola et al 2006). 
Gene 4020 (ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1): This gene 
encodes a protein or proteins that contain an ATPase, V0/V1 complex. It is implied that 
this gene is in the proton-transporting two sector ATPase complex, which is involved in 
ATP synthesis coupled proton transport. The functio of this enzyme is a hydrogen ion 
transporting ATPase activity, rotational mechanism and a hydrogen ion transporting ATP 
synthase activity, rotational mechanism protein. 
Gene 4351(protamine 1): Gene 4351 encodes a protein called Protamines. Protamines is 
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a kind of sperm nuclear protein, which is directly related with male infertility (Iguchi et al, 
2006). 
Gene 4657 (chaperonin containing TCP1, subunit 5 (epsilon)): This gene encodes a 
molecular chaperone that is member of the chaperonin containing TCP1 complex (CCT), 
also known as the TCP1 ring complex (TRiC). The complex folds various proteins, 
including actin and tubulin. Alternate transcriptional splice variants of this gene have 
been observed but have not been thoroughly characterized. 
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Chapter 8: CONCLUSION AND DISCUSSION 
 
Microarrays enable high-throughput parallel gene expr ssion analysis, and their use has 
grown exponentially during the past decade. We are now in a position where suitable data 
mining results using the public microarray datasets can be used to identify hypothesis 
about various biological mechanisms. Comparative microarray data mining could better 
distinguish phenotypes, propose new hypothesis, identify differentially expressed genes, 
and discover fundamental patterns of gene expression and regulation. 
In this chapter, we will give a brief summary of this dissertation about comparative study 
of microarray data mining, and highlight some major c ntributions. Meanwhile, some 
future research directions are also described based on the results of this dissertation. 
 
8.1. SUMMARY 
In this dissertation, we used comparative data mining methods to study certain public 
microarray datasets. Our goal is to mine intrinsic patterns from cancer related public 
microarray datasets and to provide valuable clues for biologists to further study cancer 
diseases. In order to reach this goal, we provided novel methods for testing the 
concordance of microarray datasets generated from multi-platforms and multi-
laboratories, investigating the effect of biological v riability on our data mining results, 
and finally, mining invariant patterns from multi-microarray datasets. We believe that 
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such patterns could provide valuable information for future cancer study. 
Below is a brief summary of this dissertation in a Chapter-by-Chapter manner. 
In Chapter 1, we gave the motivations and set the res arch goal for our study. We also 
highlighted the outline of this dissertation and briefly introduced the results obtained in 
this dissertation. 
In Chapter 2, we presented some preliminaries on the techniques and terminologies that 
were used throughout this dissertation. This chapter introduced the high dimensional 
microarrays, the procedure of microarray data generation, the characteristics of 
microarray datasets, emerging patterns, border differential algorithms, entropy based 
discretized method, information gain and so on. 
In Chapter 3, we surveyed the existing works related to the topics studied in this 
dissertation. We discussed the researches reported by previous papers, and most 
importantly, we identified the gaps between previous studies and our current research 
goal. What we did in our research was to fill those gaps. We focused on the following 
topics: comparative microarray gene expression data mining, feature selection, 
microarray data concordance detection, instance selection, and classification etc. 
In Chapter 4, we combined a new feature selection approach with a previous data mining 
algorithm to discover emerging patterns, which are named highly differentiative gene 
groups (HDGGs). The HDGGs mined from one dataset are considered as discriminative 
characteristic patterns and HDGGs are important featur s for each specific dataset.  
Since there are more than thousands of dimensions in microarray data, it is a big 
challenge to mine HDGGs. In Chapter 4, we introduce novel methods that did a better 
job to overcome the high dimensionality challenge. To be specific, first, we provided new 
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ideas to create a relatively small gene group called g ne club. Within one gene club, all 
genes are potentially interactive with each other. Next, we applied border differential 
algorithm to mine HDGGs from the original data projected on each given gene club. 
Some genes in mined HDGGs have been confirmed to be related with cancer diseases. 
Finally, HDGGs have also been used to build classifier , which are named HDGG-based 
classifiers.  
In Chapter 5, we provided novel measures and techniques to test the concordance of 
microarray gene expression data. Microarray data were collected using different 
microarray platforms (provided by different companies) under different conditions in 
different laboratories. It is necessary to test if hese microarray data are comparable, 
reliable and consistent before they can be applied for clinical, pharmaceutical research 
and other purposes. 
In previous studies, the cross platform and cross lab concordance of microarray data have 
been tested with many methods, such as biological experiments, statistical methods and 
so on. But the platform/lab concordance has not been examined with comparative method 
yet. It has been realized that different testing methods may lead to different results. 
Therefore, in Chapter 5, we developed several novel comparative methods to examine the 
concordance of datasets from cross platforms/labs. 
In Chapter 6, we defined the degree of variability in microarray datasets, developed 
measurements for testing the variability, and investigated the effect of variability on our 
data mining results. To be specific, we studied the eff ct of two types of variability, 
measurement variability and biological variation, in microarray datasets. 
We also provided novel method (C-loocv) to minimize th  biological variability. After 
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biological variability was minimized, the data mining results from refined datasets were 
evaluated, and showed a good improvement of the reliability. More importantly, the 
HDGG-based classifiers trained from refined datasets b came more robust, and predicted 
test samples with much higher accuracy. 
In Chapter 7, we discovered certain invariant patterns from multiple microarray datasets 
concerning a common disease. We studied two microarray datasets derived from the 
samples of patients with common disease. These datasets were generated from a common 
platform but different laboratories. We mined HDGGs from each dataset and discovered 
the shared gene interactions (which are called invariant patterns) by comparing these 
HDGGs’ generality and specificity among different datasets. Since variability affects the 
data mining results, the invariant patterns should be more reliable to provide useful 
information for understanding the potential gene pathw ys for diseases. 
In the above 7 chapters we presented our approaches for comparative microarray data 
mining. Experimental evaluations have been conducte for those proposed approaches, 
and the results showed that our approaches are very promising and effective. However, 
limitations were also observed in some of the approaches, which have been suggested as 
potential future works. 
 
8.2. CONTRIBUTIONS 
Overall, we made the following contributions in this dissertation: 
(1) We conducted extensive study to mine HDGGs from high dimensional microarray 
datasets. Our methods are better than previous studie  in many ways including: (A) we 
improved the strength of discovered patterns compare with previous studies; (B) we 
 129 
discovered strongest HDGGs (100% frequency); (C) our HDGGs were proven to be 
biological meaningful; (D) the discovered HDGGs were used to build the so-called 
HDGG-based classifiers, which showed higher predicting accuracy on many public 
microarray datasets compared with other classifiers. 
(2) Using comparative methods, we quantitatively tested the concordance of microarray 
datasets collected from same/different platforms and different laboratories. This was the 
first attempt to use comparative methods for evaluating microarray dataset concordance. 
We tested four popular, commercial platforms: Applied Biosystem (ABI), Affymetrix 
(AFX), Agilent one color array (AG1) and GE Healthcare (GEH). Our results showed 
that the datasets from any common platform but different laboratories were highly 
concordant; the datasets from different platforms were also concordant with each other 
except the datasets generated from the Agilent one c lor array platform. 
(3) This dissertation was the first attempt to defin  the degree of variability, measure the 
effect of variability on data mining results, and mini ize variability in microarray 
datasets. After variability was minimized by C-loocv algorithm, the data mining results 
from datasets became more consistent. Furthermore, the robustness of our HDGG-based 
classifiers built from C-loocv refined datasets was significantly improved. 
(4) We provided novel method to mine high quality patterns from highly variable 
microarray datasets. The so-called “invariant patterns” have been proven to be more 
reliable for helping understand diseases, and they tend to be potentially important for the 
occurrence of diseases. 
We believe that those contributions not only are usful for DNA microarray dataset 
studies, but also provide valuable information for pharmaceutical and clinical research. 
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8.3. FUTURE WORKS 
While the work in this dissertation has addressed many problems of current microarray 
data mining, it could only do so with a limited depth. We believe that this dissertation has 
laid the foundation for a wide variety of potential research and applications. There are 
several relevant research topics that remain open: 
A. Classification method improvement 
In microarray data study, good classifiers are very important for accurately predicting the 
samples (patients) and diagnosing the diseases. Many cl ssification methods have been 
developed. Currently, no classifier can predict the test samples with 100% accuracy in 
any datasets. Therefore, newer classifiers with higer predicting ability still need to be 
developed. HDGG-based classifiers building from HDGGs have been proven to be very 
robust. Invariant patterns can be used to improve the reliability of HDGG based 
classifiers.  IVP-based classifiers building from IVPs are expecting to be more reliable. 
B. Studying more microarray datasets which focus on any common 
disease 
In this dissertation, we provided generic methods t effectively identify valuable patterns, 
aiming to shed light on the intrinsic mechanism underlying diseases of interest. For our 
study, we used lung cancer related microarray datasets to mine invariant patterns. For 
future research, our methods may be employed for mic oarray datasets concerning other 
tumors or diseases. When IVPs are mined from multi-microarray datasets which study a 
common disease, they will be of great help for understanding the mechanism of any 
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given diseases. 
 
C. Comparative study on multiple diseases 
It is also desirable to study microarray datasets which study multiple diseases. By 
comparing IVPs’ generality and specificity among the datasets which study different 
diseases, the shared and unique gene interactions may be discovered and the shared and 
unique gene networks may be established. The information for the potential gene 
pathways for the set of diseases may also be provided. 
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